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Women with cystic fibrosis (CF) now regularly survive into their reproductive years in good health and wish to have a baby. Many pregnancies
have been reported in the literature and it is clear that whilst the outcome for the baby is generally good and some mothers do very well, others find
either their CF complicates the pregnancy or is adversely affected by the pregnancy. For some, pregnancy may only become possible after
transplantation. Optimal treatment of all aspects of CF needs to be maintained from the preconceptual period until after the baby is born. Clinicians
must be prepared to modify their treatment to accommodate the changing physiology during pregnancy and to be aware of changing prescribing
before conception, during pregnancy, after birth and during breast feeding. This supplement offers consensus guidelines based on review of the
literature and experience of paediatricians, adult and transplant physicians, and nurses, physiotherapists, dietitians, pharmacists and psychologistsAbbreviations:%FEV1, % forced expiratory volume in 1st second (as predicted for age, sex and height); %FVC, % predicted forced vital capacity (as predicted for
age, sex and height) (as predicted for age, sex and height); ACT, airway clearance therapy; BiPAP, bilevel positive airway pressure; CF, cystic fibrosis; CFLD, CF liver
disease; CFRD, CF related diabetes; CI, confidence interval; CVS, chorionic villus sampling; DPI, dry powder inhaler; EFA, essential fatty acid; FRC, functional
residual capacity; GP, general practitioner; IU, international units (e.g. of vitamins); IV, intravenous; MDI, metered dose inhaler; OGTT, oral glucose tolerance test;
PEP, positive expiratory pressure; PERT, pancreatic enzyme replacement therapy; RV, residual (lung) volume; SaO2, arterial oxygen saturation; TLC, total lung
capacity.
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S3F.P. Edenborough et al. / Journal of Cystic Fibrosis 7 (2008) S2–S32experienced in CF and anaesthetist and obstetricians with experience of CF pregnancy. It is hoped they will provide practical guidelines helpful to
the multidisciplinary CF teams caring for pregnant women with CF.
© 2007 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Pregnancy; Breast feeding; Cystic fibrosis; Transplantation; Management; Guidelines1. Introduction
Overall survival with cystic fibrosis (CF) has improved due to
early diagnosis, early instigation of effective and aggressive
management of nutrition and respiratory infection, and multi-
disciplinary working in specialised centres. Regular screening
allows early intervention for other complications including
diabetes, liver disease and osteoporosis. It is now normal for
children to survive to adulthood, frequently with near normal
weight and lung function and early suggestions of reduced
fertility [1] have been shown to be unfounded. Pregnancy is
commonplace and even those with advanced lung disease can
carry pregnancy to a successful outcome [2]. Where infertility is
an issue, artificial reproductive techniques can facilitate preg-
nancy [3] (unless infertility is caused by secondary amenorrhoea
due to severe disease) and following lung transplantation there
may be a second chance for a woman to consider a child [4].
The North American Cystic Fibrosis Foundation Patient
Registry has reported approximately 140 pregnancies per
annum since 1991 equating to 3–4% of women aged over 17
becoming pregnant each year. Thus pregnancy in women with
CF is increasingly common and most adult CF centres and
many paediatric centres will have had to care for a woman with
CF and her pregnancy.
Whilst pregnancy is well tolerated by women in good health,
with good outcomes for the baby, many women do experience
difficulties including maintaining adequate nutrition and an
unpredictable effect on lung function. Pregnancy should be
carefully planned taking into consideration genetic issues, the
possible effects of CF or its treatments on the foetus, counselling
regarding the advisability of pregnancy in those less well, and
considering who will care for the mother and child should the
mother become unwell. Patients should be closely monitored
during pregnancy with particular emphasis on nutrition and
weight gain, regular review by physiotherapists to optimise
physical therapy and prompt attention to respiratory exacerba-
tions. Management of women with nutritional difficulties, diabe-
tes, poor lung function or pulmonary complications may be very
difficult. Obstetric practicemust take into consideration the health
of not just the baby but its effect on the mother's CF. Relatively
little data exists regarding the outcome for mothers and almost
none on the outcome of infants beyond the neonatal period.
2. Historical perspective
As survival improved and the number of adolescents in-
creased, pregnancy in women with CFwas inevitable and the first
mother with CF was reported in 1960 [5] with the first review of
ten cases in 1966 [6]. The details of these first ten mothers is
lacking with respect to height, weight, pulmonary function andpancreatic status however the report is instructive and sets the
scene for all further studies. Of these first ten mothers, seven had
been diagnosed age 16 or older, one being diagnosed during her
pregnancy, and the mean age at pregnancy was 21.5 (19–32)
years. Two were diabetic, with one developing gestational
diabetes. Delivery of ten infants (one stillborn) occurred at
mean 36 (range 23–40) weeks gestation, eight by spontaneous
labour, with mean birth weight of 2.6 (range 1.5–3.6) kg for those
live born. One child died in the neonatal period, none of the eight
remaining had CF. No further details are given of the infants.
The mothers could be divided into two groups; five with no
discernible effect of pregnancy on their lung function (group 1),
and five with a significant decline in lung function (group 2). In
group 1, none had diabetes, four out of five reached term, none
experienced a decline in lung function and two mothers went on
to have one or two further successful term deliveries. In contrast
two in group 2 had diabetes, none reached term, four died
between five days and 18 months post-delivery and none had a
further pregnancy. The stillbirth and neonatal death both oc-
curred in group 2.
The authors concluded that whilst pregnancy was possible
and well tolerated in those with mild disease, those with poor
lung function, severe forms of the disease (judged by early
diagnosis) and diabetes were likely to do badly with increased
risk of infant prematurity and death, and maternal loss of lung
function with accelerated decline after pregnancy. By and large
this message is repeated in every single study since, with some
notable additions.
3. Introduction to the guidelines
Most of the literature on pregnancy in CF is in the form of
case reports, individual centre reports of their experience, a few
national centre based reviews and some database derived series.
There are a few case based discussions of complex clinical
problems in pregnancy in CF including diabetes, respiratory
failure, nutritional failure etc and fewer still of obstetric and
therapeutic interventions. There have been no trials of any
aspect of pregnancy management in CF. Several authors [2,7,8]
have tried to pull together summaries of what is known to date
about pregnancy in CF and offered suggestions for optimising
management but no formal consensus guidelines exist. The
purpose of this document is to make broad based, multidisci-
plinary recommendations for the management of pregnancy in
CF which should be undertaken in specialist CF centres.
3.1. Method of compilation
The work was commissioned by the European Cystic
Fibrosis Society (ECFS) and interested parties (see contributors,
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by Marie Johannesson and the writing coordinated and edited
by Frank Edenborough. Authors were invited to write to their
areas of expertise. Individual authors reviewed the literature and
attempted to distil best practice. The guidelines were reviewed
internally by the group before dissemination to a wider group
of experts for comment. It was deemed unnecessary and
impractical to attempt to conform to the Scottish Intercollegiate
Guidelines for ascertaining levels of evidence as so little hard
data exists and these guidelines therefore represent expert
consensus.
3.2. Notes on recommendations for drug use in pregnancy and
breast feeding
Most medicinal products, unless specifically intended for use
during pregnancy, have not been tested on pregnant women.
Indeed, drug testing protocols usually require women of
childbearing age to be using effective contraception and have
negative pregnancy tests. Thus, most data available to evaluate
reproductive risk come from studies in animals, preclinical
studies or from post-market surveillance.
General considerations regarding the information on
drug exposure in pregnancy include the timing of exposure
(periconception, first, second, third trimester or perinatally),
systemic availability of the drug, the ability of the drug to cross
the placenta, the likely spectrum of effects from teratogenesis
during the period of organogenesis (days 15–60 post-fertiliza-
tion) which may induce major malformation, growth retardation
or death, to later exposure when the consequences may include
growth retardation, renal insufficiency, neurological disorders,
stillbirth, etc.
Many pregnancies are unplanned and drugs have been taken
at the time of conception and continued in the first weeks of
pregnancy, and many women with serious illnesses have re-
quired treatment to be continued because the greatest risk to the
foetus was posed by the illness. Thus there is experience and
information to guide prescribing in pregnancy although the
principle remains to avoid drug use where possible except when
the risk of the drug is outweighed by the risk of the condition
being treated.
3.2.1. Sources of human pregnancy data
Existing sources include databases of national regulatory
authorities, national congenital anomaly registries and the
PedTox registry in the US. Data are often limited to spontaneous
reports of adverse outcomes and may be biased. The anomaly
registries are used for conducting case-control studies. Pro-
spective pregnancy exposure registries for screening and ana-
lysis have been used to identify and estimate risks associated
with exposure to drugs. Possible sources for European registry
studies include the Swedish Medical Birth Registry and a
smaller registry, the Danish Medical Birth Registry.
3.2.1.1. The Swedish and the Australian classification. Since
1978, the Swedish FASS (www.FASS.se) drug information
catalogue has provided information derived from manufacturerson the risks of drugs to the foetus during pregnancy and to the
infant during lactation. Each drug is classified to one of four
categories of safety in pregnancy:
A. Drugs that have been used widely during pregnancy and
are assumed safe for the foetus
B. Drugs not known to cause harm to the human foetus but
with insufficient experience to consider them safe. This
category can be subdivided into
B1 drugs that have been demonstrated to cause no harm
in animal studies
B2 drugs with insufficient animal data
B3 drugs that have been demonstrated to harm the foetus
only in animal studies
C. Drugs that could theoretically cause harm to the foetus by
their pharmacological actions
D. Drugs known or believed to cause harm to the foetus.
The Australians have added another category: www.tga.gov.
au/docs/html/mip/medicine.htm.
X. Drugs that carry such a large risk for irreversible damage
to the foetus that they may not be used during pregnancy.
Ultimately when considering which drugs to stop or which to
use in pregnancy the clinician must weigh the risk of the drug to
the foetus against the risk to mother and foetus if her condition
deteriorates.
Recommendations made in the text and in Appendix C are
based on many sources; the lists are not fully inclusive and there
are areas where data is conflicting so advice to an individual
patient will depend on their individual circumstances and the
caveats discussed with their clinicians.
4. The woman with CF planning a pregnancy
4.1. Coordinating CF care (see Appendix A)
Planning a pregnancy takes time and effort. The nurse
perhaps more than any other team member may find him/herself
in the role of coordinating the necessary changes in CF care. This
role involves practical nursing issues, pastoral and organisa-
tional roles, and in particular liaison with other members of the
CF team and particularly with new members of the team
including genetic counsellors, obstetricians, obstetric anaesthe-
tists and midwives. Coordination of appointments is helpful,
especially as the pregnancy progresses. Good communication
between the obstetric and CF teams and the general practitioner
(GP) throughout the pregnancy ensures that the mother's health
remains stable.
4.1.1. Nursing issues when supporting women planning a
pregnancy
At this time of excitement and planning for the future, the
realities of CF must be discussed with the young couple. They
will need to consider where they will get both ongoing practical
and psychological support, the implications of potentially
becoming a one parent family, financial support and planning
for the child's future. Women who are in employment may need
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early discussion with employers helps this transition. Regular
outpatient attendance must be encouraged particularly in the
latter stages of the pregnancy.
Taking care of a toddler takes time, interrupts all daily
activities including treatment. The partner should be advised
that the mother will need to plan time for herself to carry out
regular treatment and to rest. This is essential to maintain best
possible wellbeing. Home care support should be considered
and if they plan for external day care for the child, they should
be informed about the common problem of recurring infections
in bigger groups of small children, and perhaps consider a day
nursery, a “day mother” or some other form of day care in small
groups.
4.2. Counselling
Counselling in its broadest sense involves helping the
woman with CF planning a pregnancy and her partner to
understand the implications of their decision making. The
medical facts, probable course of the disease, treatment options,
the effect of CF on pregnancy, the effect of pregnancy on CF
and the impact of an active toddler on every day life should be
discussed. The genetic implications of the disease and the risk
of recurrence in their children and options for dealing with this
risk are discussed against the background of their family goals,
their ethical and religious belief/standards and from these
discussions a course of action is decided upon.
4.2.1. Genetic counselling
The woman's CF genotype if not already known should be
determined. Her partner should be tested and the implications of
this discussed. The infant will at least be a carrier of CF and has
a 1:2 chance of having CF itself if the father is a carrier. Over
1400 gene defects have been described (see www.genetic.
sickkids.on.ca) but unfortunately significant discrepancies
between genotype and phenotypic expression exist, particularly
with severity of pulmonary disease, the primary cause of
morbidity and mortality [9]. Thus genetic counsellors should be
cautious about estimating the likely clinical severity based on
genetic data and avoid using available generalised data as a
basis for predicting the individual clinical course of a child born
with CF [10].
4.2.1.1. Risk of CF in a child born to a mother with CF. In
some populations there is great heterogeneity of the CF gene
and not all mutations are known and not all can be routinely
tested for. The sensitivity of genetic testing is b100% and will
vary with a detection rate from 70 to 95% of mutations in
different populations. Given a CF carrier frequency of 1:25, the
risk of an infant with CF is 1:50 if the partner comes from the
general population and is not tested. If the partner is found to be
a CF carrier, the risk is 1:2 and if no mutation is detected his risk
of being a carrier is reduced from 1:25 to 1:165, 1:246, 1:491,
(using 85%, 90% or 95% sensitivity test respectively) and the
risk to a couple of a baby with CF is correspondingly reduced to
1:330, 1:492, 1:982 [11].4.2.1.2. Prenatal genetic diagnosis. If the genotype of both
partners is known and no abnormality has been found in the
partner, no further data about CF recurrence risk can be obtained
analysing foetal genotype, therefore prenatal diagnosis is not
indicated. If the partner is a carrier, or if a woman is pregnant
and the partner's genotype is unknown and cannot be tested,
prenatal diagnosis by genetic analysis of chorionic villus sample
(CVS) can be performed, ideally within the first trimester. This
will ascertain if the foetus has CF. If the partner's known
mutation is not found the foetus is a confirmed carrier, but
where the partner has no recognised mutation or his genotype is
unknown the risk of CF is substantially reduced but not zero as
there remains the possibility of an unidentifiable mutation. The
couple should be informed about the medical and technical
aspects of prenatal diagnosis, including risks of the procedure,
diagnostic accuracy, the availability of selective termination of
pregnancy, its timing and the available techniques in case CF is
diagnosed in the foetus [12,13]. However, it is noted that some
couples choose not to have genetic testing since they would not
consider termination even if the child had CF.
4.2.2. Psychosocial counselling (see Appendix B)
Young women with CF have been shown to start sexual
activity at the same time as otherwise healthy young females,
but are less likely to use contraception and often have poor
understanding of the risks of pregnancy [14]. There is also
evidence [15] that young people with CF do not always have
full and accurate information about reproductive and sexual
health issues, and feel they have not had sufficient opportunity
to address these areas.
CF teams need to provide high quality information about
sexual health and reproduction. A sample of teenage girls with
CF suggested this takes place around age 13 though their
mothers wanted discussion with parents earlier than this [15],
thus there is a need for information about fertility and repro-
duction. A sample of teenage girls with CF suggested this takes
place at age 12–13, though their mothers wanted relevant
information earlier than this [16]. Provision of information
about sexual health and reproduction by the CF team should
start in early adolescence, be tailored to each individual's age,
understanding and development, and continue on a regular
basis. When actively considering a pregnancy, discussion with
the partner present should be offered whenever possible. Con-
sideration of the main psychological issues may necessarily
focus on the possible negative aspects of pregnancy in CF but
will be weighed against all the potential positives of having a
child. See Appendix B for areas to discuss over time.
Whilst it is recommended that all women with CF con-
sidering pregnancy consult with their medical teams, some may
not. Some women need to hear honest information even if
difficult, others resent perceived interference in what may be
felt to be a very personal and private decision [15]. Individual
differences will also influence discussions. Those that cope with
CF mainly through avoidance or minimisation may find open
discussion of potential problems particularly difficult. Others
may have an inaccurate view of their health status through
denial or lack of accurate information. Women with anxiety or
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those that had difficult childhoods may long for a child most
strongly, as a source of love and affection.
Women are more likely to approach the CF team in advance
of pregnancy if there is an open, honest and trusting relationship
with that team, and if they are confident that their right to make
choices will be respected, even if these do not correspond to
medical advice. The aim will be to provide information so that
women and their partners can make informed decisions for
themselves. For those in relatively good health discussions may
be easier, though there should still be the opportunity to discuss
difficult issues e.g. the possibility of the mother dying whilst
children are still young. For women with more advanced disease
discussions and decisions may be very difficult and may include
advice against pregnancy on medical grounds. Women with a
very strong drive to have a child may proceed whatever the
advice. Some will follow medical advice and make a positive
decision not to have children, others will find it very hard to
cope with this outcome. Further psychosocial support may be
necessary where there is significant grief at the loss of the
chance of a child, anger at the CF team or CF itself, and to help
make healthy adjustment by identifying alternative directions
for the future.
Psychological support should therefore be available and may
be provided by different members of the CF team. Specialist
psychological intervention may be necessary e.g. from appro-
priately trained professionals such as a Clinical Psychologist
where there is significant depression, anxiety, grief, anger or
difficulty in adjusting to events [17]. Access to a specialist
social worker may also be necessary for advice on specific
issues such as financial changes for the family access to child-
care, relevant disability legislation. In some countries those with
CF may be able to access locally produced information that
draws on the invaluable experience of others with CF, as well as
providing medical information and questions to consider.11
4.3. Optimising preconceptional health and treatment
4.3.1. Use of drug therapy in pregnancy (see Section 3.2 and
Appendix C)
When discussing a potential pregnancy, the patients
medication should be reviewed with careful attention to include
non-prescription “over the counter” treatments and herbal or
vitamin preparations. Most routine CF drugs are safe and should
be continued. Where there is doubt a decision based on risk:
benefit will need to be agreed with the patient. Contraindicated
drugs should be stopped and an alternative sought or the
condition monitored.
Many women are aware that in general drugs should be
avoided in pregnancy and will take it upon themselves to stop
their treatment and adherence should be carefully monitored
and regularly discussed.11 UK publications “Can I and should I have a baby” Barnardo's Childcare
Publications, Basildon, 2001; “Growing Older with CF” and “My Mummy has
CF” both published by Cystic Fibrosis Trust, Bromley, 2000.4.3.2. Optimising lung function
Women with all stages of pulmonary disease have become
pregnant. The literature suggests that outcome for mother and
infant is closely related to both absolute lung function and the
stability of the lung disease. Thus lung function should be
optimised in all women before pregnancy, and infection treated
aggressively during pregnancy. There are however no published
guidelines on how to proceed.
4.3.2.1. Suppression of chronic infection. Chronic infection
with Staphylococcus aureus may be suppressed with oral
Flucloxacillin or treated on each isolation according to local
practice. Pseudomonas aeruginosa is usually suppressed with
nebulised colistin or an aminoglycoside. There is no data on
nebulised colistin but experience suggests this is safe in preg-
nancy. Inhalation of 80 mg tobramycin twice daily in 14 patients
resulted in 50 of 70 serum levels below the minimal detectable
value of 0.1 mg/l [18]. However, the newer high-dose formu-
lations of tobramycin do result in low but measurable levels of
drug (mean serum concentration of 0.95 mg/l 1 h after the dose),
thus tobramycin levels should be measured and consideration
given to either stopping the drug or changing to low dose
preparations at least during the first trimester of pregnancy [19].
4.3.2.2. Acute infection. If a woman actively trying to become
pregnant develops an acute exacerbation she should be advised
to use barrier contraception rather than risk a pregnancy be-
ginning whilst she is unwell. Antibiotics should be used and
barrier precautions probably continued for 1 week after the
course is completed (see Section 7.3.2 for treatment if she is
already pregnant).
4.3.2.3. Inflammation. Inflammation as the consequence of
infection leads to ongoing lung damage and in some is linked to
irritable reversible airways disease. Inhaled corticosteroids are
thought safe following considerable experience in asthma [20].
Oral steroids are associated with teratogensis in animals, may be
associated with cleft lip and palate in humans and should
probably be avoided (but not discontinued if part of long-term
therapy) in the first trimester. Azithromycin has been used in
short courses to treat sinus infection during pregnancy and is
probably safe but there is little data on general safety and none
in pregnancy of its long-term use as in CF [20].
4.3.2.4. Mucolysis. There are no data on inhaled dornase alfa
safety in pregnancy however it is unlikely to affect the foetus
and has been continued in pregnancies in CF.
4.3.2.5. Reversible airway disease. Sympathomimetics and
parasympatholytic drugs are thought to be safe and may be used
if indicated [20].
4.3.3. Considerations for the physiotherapists (see Appendix A)
The preconceptional period represents another opportunity
to assess the patient's daily physiotherapy routine and update it
with emphasis on continuation after delivery. In severely ill
patients supplemental oxygen or even non-invasive assisted
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treatment. It is emphasised that the timing, duration, choice and
use of inhalation devices, physiotherapy aids and exercises are
tailored to the individual and each stage of her pregnancy.
4.3.3.1. Optimising inhalation therapy. Inhalation therapy,
inhaler devices, handling and inhalation technique should be
reviewed and optimised. The most appropriate and time-effi-
cient inhaler device(s) should be chosen where alternatives
exist. The time for maintaining and cleaning a nebuliser system
should be taken into consideration when choosing a device. A
reversibility test documenting the effects of bronchodilators
should be considered. The timing of inhalation therapy in rela-
tion to airway clearance therapy (ACT) is essential especially in
those women producing large volumes of sputum. Some drugs
should be inhaled prior to, others in combination with ACT and
others should be inhaled when the lungs are as clear as possible
[21].
4.3.3.2. Airway clearance therapy (ACT). The quantity,
quality and adherence to the recommended ACT are assessed,
adapted and optimised. Several different airway clearance
therapies used alone or in combination, with or without devices
may be introduced [22] to get air behind secretions, loosen,
transport and then evacuate them by controlled cough.
Strategies should use as much of the lung volume as possible,
utilise the effects of gravity on regional lung volumes and
ventilation distribution and strive to find the optimal expiratory
flow velocity at different lung volumes.
4.3.3.3. Physical exercise. Mobility and postural muscle exer-
cises for the chest wall, spine and shoulders, strengthening
exercises for postural muscles as well as exercise capacity
training should be encouraged, if not already part of the therapy,
for they also provide respiratory muscle training. Muscle
strengthening exercises for the lower limbs are of great value
and training of the pelvic floor should be started on as soon as
possible. Physical exercise may need to be discussed with the
dietitian if the patient has diabetes or if the nutritional status is
compromised.
4.3.4. Optimising nutrition (see Appendix E)
Malnutrition in CF is multifactorial and remains a concern
with 24% of adults in the United Kingdom (UK) having a BMI
b19 kg/m2 [2,23] despite active intervention in CF Centres.
Regular dietetic counselling focusing on optimising energy and
nutrient intakes is especially important in the preconceptional
period and should be aimed at optimising maternal health and
fertility and the prevention of neural tube defects. Maternal
nutrition is regarded as one of the most important environmental
factors influencing the evolution of any pregnancy and con-
sequently the outcome for the baby. Pregnancy in adolescence is
a particular risk because girls may enter pregnancy with low
nutrient reserves due to the increased requirements of their
growth spurt. Multiple pregnancies are possible though women
who have a short inter-pregnancy interval may not have time for
nutrient repletion [24]. In a survey of mothers with CF in theUK preconceptional nutritional advice has been shown to be
associated with greater weight gain during pregnancy and
heavier babies [25].
4.3.4.1. Preconceptional nutritional assessment and manage-
ment in CF. Recommendations are based on those for the non-
CF population adapted according to our understanding of the
additional nutritional requirements in CF. A thorough precon-
ceptional nutritional assessment should be carried out at a
Specialist CF Centre by the CF Specialist Dietitian [26].
4.3.4.2. The importance of optimal nutritional status. In
women with CF with good lung function and a normal BMI
menstruation and ovulation are likely to occur normally
[27]. Suboptimal nutritional status is associated with secondary
amenorrhoea and a reduced ability to conceive [28] and low pre-
pregnancy BMI is consistently associated with reduced birth
weight [29]. Though unusual in CF, being overweight can also
reduce fertility and increases the risk of complications such as
high blood pressure, infections and diabetes during pregnancy.
4.3.4.3. Maximising dietary intakes. The dietitian can advise
on increasing the energy density of the diet by dietary mani-
pulation. If nutritional status and BMI cannot be optimised by a
high energy diet then oral nutritional supplements or more
invasive nutritional support may be considered.
4.3.4.4. Oral nutritional supplements. Nutritional supple-
ments should be prescribed on an individual basis depending on
the woman's weight, requirements, clinical condition and pref-
erences. Alternating the flavour and type of supplement may
help to prevent taste fatigue, and experimentation may be
necessary particularly if nausea becomes a prominent feature.
4.3.4.5. Enteral tube feeding. Enteral tube feeding in CF
improves weight gain and nutritional status [30,31]. If enteral
tube feeding is required to maintain nutritional status prior to
conception it may prove very difficult to achieve the increased
energy requirements of pregnancy and to optimise weight gain.
4.3.4.6. Vitamin supplementation
4.3.4.6.1. Folic acid. Folic acid, a water-soluble B vita-
min, occurs naturally in food as folates. Preconceptional folic
acid deficiency has been demonstrated to have a causal role in
neural tube defects [32]. To prevent neural tube defects, it is
recommended that all women who are planning a pregnancy
take a daily supplement of 400 mcg of folic acid in the pre-
conceptional period and throughout the first trimester [33,34],
or 4000–5000 mcg/day if considered to be at high risk for an
affected pregnancy [34].
4.3.4.6.2. Vitamin A. Both severe vitamin A deficiency and
excess are teratogenic and associated with adverse reproductive
outcomes [35]. Supplemental intakes of vitaminA ofN10,000 IU/
day have been associated with an increased incidence of birth
defects in the non-CF population [36]. Women in the United
Kingdom who are or might become pregnant have been re-
commended not to take supplements containing vitamin A unless
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people with CF and can be of concern to many pancreatic
insufficient females who will routinely be taking supplements of
the fat-soluble vitamins A, D, E, and possibly K. Assessment of
vitamin A intake and status should be undertaken in the pre-
conceptional period and vitamin A supplementation should
continue at b10,000 IU/day.
4.3.4.6.3. Vitamin D. It is recommended that pregnant
women should receive supplementary vitamin D to achieve an
intake of 10 mcg/day (400 IU) [38] although a recent Cochrane
review concluded there is insufficient evidence to evaluate the
requirements and effects of vitamin D supplementation in
pregnancy [39]. It is likely that a supplemental dose greater than
10 mcg/day is required to improve circulating levels of 25-
hydroxyvitamin D [40–43] in CF. Vitamin D levels should be
measured and supplemented if low and supplementation should
also be considered in pancreatic sufficient women who may not
take them routinely.
4.3.4.6.4. Other vitamins. It is essential to review all non-
prescription, over the counter and herbal vitamins/products that
women may be taking.
4.3.4.7. Other nutritional risk factors. As with the general
population in the preconceptional period advice is needed re-
garding alcohol, caffeine and fish consumption, food borne
illness and food safety.
4.3.4.7.1. Caffeine. High levels of caffeine have been as-
sociated with reduced fertility, although studies are confounded
by other factors such as smoking and high alcohol intakes.
Women who are planning a pregnancy or who are pregnant
should limit their caffeine intake.
4.3.4.8. Food borne illness and food safety. Preconceptional
counselling can increase awareness of the types of food borne
infections that have the potential to cause death, or damage to
the foetus.
4.3.5. Optimising diabetes care
4.3.5.1. Diabetes in pregnancy in CF. In Grand's first case
series [6] the two mothers with CF related diabetes (CFRD)
were in the group that did less well. Subsequent studies
confirmed that diabetes was associated with a poorer prognosis
whether diagnosed pre-pregnancy or developing as gestational
diabetes. In one study [44] women who became pregnant with
diabetes were compared with those who did not have diabetes
and did not develop gestational diabetes. Although the diabetic
women were slightly heavier than the non-diabetic mothers they
were of a similar age and had similar lung function. Despite this
they were more likely to have premature deliveries requiring
caesarean section (unpublished data). This is perhaps unsur-
prising since diabetes confers greater risk in non-CF pregnan-
cies and poor glycaemic control in the first trimester increases
the risk of foetal anomalies ten fold [45].
4.3.5.2. The metabolic effects of pregnancy in CF. Studies of
glucose metabolism in CF reveal reduced insulin secretion,increased peripheral and hepatic glucose resistance with in-
creased hepatic glucose production and greater protein catabo-
lism. In pregnancy insulin secretion is enhanced with normal to
decreased insulin sensitivity. Any insulin resistance that
develops in late pregnancy is compensated for by the increased
secretion. Women with CF have been studied in pregnancy and
shown to be unable to match the normal response and hence are
at increased risk of gestational diabetes and enhanced protein
catabolism with impaired weight gain [46].
4.3.5.3. Diagnosis of glucose intolerance and/or gestational
diabetes. If a woman comes for preconceptional counselling
and an OGTT has not been performed, one should be and blood
sugars carefully monitored during infective exacerbations. It is
usual to repeat the OGTT at 20 weeks gestation. The sugar
should be measured at every visit and consideration given to
repeating theOGTTat 28weeks or if random sugars are elevated.
4.3.5.4. Treatment of diabetes in pregnancy. Whether diabe-
tes is established, newly diagnosed or gestational, insulin is the
preferred form of treatment, with short acting forms preferred
and taken immediately after food if nausea and vomiting make
intake unpredictable. If sulphonylureas are used during preg-
nancy they should be discontinued ∼48 h prior to delivery and
insulin instigated to minimise the risk of neonatal hypoglycae-
mia in the infant.
4.3.5.5. Optimising nutrition in diabetes. A high calorie
intake should be maintained. Simple sugars should be taken at
mealtimes where possible together with more complex
carbohydrate, and supplements if used may need to be changed
from high sugar to more balanced polymeric forms. Low sugar
drinks should be considered although standard forms may be
taken with a meal. Poor weight gain should prompt consider-
ation of nutritional supplements, or supplemental nasogastric or
gastrostomy feeding at an earlier stage than for non-diabetics
which in turn will require modification of the insulin regimen.
There should be close liaison between the CF dietitian and the
diabetes team, preferably with access to a physician or nurse
with particular expertise in diabetic pregnancy.
5. The woman who presents already pregnant
Despite providing information and support to both young
adults and their parents about pregnancy and fertility in CF, there
will continue to be some women who present already pregnant.
There are many reasons that young women with CF get
pregnant, for some it is a genuine accident, some do not listen or
remember advice and some want to get pregnant despite advice.
Many women without CF talk about a ‘biological clock’ that
influences their need to have children; women with CF are not
immune to this. Wanting to be ‘normal’, to be the same as peers,
to leave something of themselves behind, and family pressure
have all been given as reasons for pregnancy. Whatever the
reason it is important that the young woman with CF who
presents pregnant should feel that they have the full support of
the CF team.
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Much of the need for coordination of care remains even
when a woman presents already pregnant although the stage of
the pregnancy will influence what is possible. Urgent attention
to the genotype of mother and partner is required especially if
the woman is uncertain about how far pregnant she is and the
couple would consider termination if the foetus proved to have
CF. Health status must be optimised and if the woman is unwell
her health should have priority over that of the foetus. A plan of
continuing care and delivery should be discussed with the
woman (and her partner), the CF team and the obstetric team.
5.2. Counselling
5.2.1. Genotype — hers and her partners
If the woman presents already pregnant and her genotype is
unknown it is important to genotype her and her partner as soon
as practical. If the partner is negative, no further tests are
required but if he is a carrier or he is unavailable for testing
consideration needs to be given to antenatal diagnosis via
chorionic villus biopsy or amniocentesis.
5.2.2. Psychosocial issues (see Section 4.2 and Appendix B)
Whether a woman presents with an unplanned pregnancy or
an intended pregnancy with conscious avoidance of medical
advice/intervention, psychosocial considerations will be equally
important. In these situations urgent attention will need to be
paid to issues around the pros and cons of proceeding with the
pregnancy with support for those who choose/are advised to
have a termination of pregnancy and the genetic implications for
the infant if the pregnancy continues. Thereafter the patient and
the CF team will need to come to terms with a pregnancy
proceeding against advice and the need to support the patient in
any decisions regardless of these views.
5.3. Optimising health and treatment
5.3.1. Optimising medication
See Section 3.2 and Appendix C.
5.3.2. Optimising lung function (see Section 4.3.2 and
Appendix D)
When a pregnancy is unplanned or the CF team has been
deliberately excluded from preconceptional counselling, it is
frequently a deterioration in the chest that leads to attendance at
the CF Unit. A course of intravenous (IV) antibiotics is often
required and should follow the usual format (β-lactam
+aminoglycoside). Significant lung infection poses a risk to
the foetus and the most potent antibiotics should be chosen
since the risk from the mother's illness is likely to outweigh the
theoretical risk of the medication
5.3.3. Considerations for the physiotherapist (see Section 4.3.3
and Appendix D)
Should the decision be made to continue the pregnancy,
assessment of current inhalation and airway clearance therapiesand their modification according to need and the stage of preg-
nancy should be made using the principles outlined in Section
4.3.3 but if presenting late into pregnancy other complications
relevant to the physiotherapist may arise (see Section 7.3.3).
Advice on physical exercise and on pelvic floor strength and
control should be given as soon as possible. The demands made
by the rapidly changing physiology may be difficult to come to
terms with if preconceptional discussions have not taken
place and additional support from the physiotherapist may be
required. The couple will be encouraged to attend ordinary
childbirth preparation classes, often provided by specialist
physiotherapists.
5.3.4. Optimising nutrition (see Section 4.3.4 and Appendix E)
If a woman presents already pregnant it is essential that a
dietary assessment is undertaken by a CF Specialist Dietitian
similar to that undertaken for preconceptional counselling at the
earliest opportunity. Folic acid supplementation should contin-
ue to the 12th week with dietary advice aimed at increasing
dietary folic acid/folate intake. Vitamins A and D levels should
be measured and vitamin A supplemental doses kept at less than
10,000 IU/day and vitamin D increased as required. All non-
prescription, over the counter and herbal vitamins/products
should be reviewed.
5.3.4.1. Optimising nutritional status. Although a low pre-
pregnancy BMI is consistently associated with reduced birth
weight [47], the effects of this can be offset by a higher level of
weight gain during pregnancy. Optimising nutritional status is
even more pressing in those who present already pregnant.
5.3.4.2. Other nutritional issues. As with the general popu-
lation advice is needed regarding alcohol, caffeine and fish
consumption, food borne illness and food safety.
5.3.5. Optimising diabetes care (see Section 4.3.5)
Poor glycaemic control in the first trimester is associated
with an increased risk of teratogenesis [48]. If a woman presents
already pregnant and her glycaemic status is unknown an oral
glucose tolerance test should be done as soon as possible [49].
Women with established CF related diabetes, those with known
impaired glucose tolerance prior to conception and those with
impaired OGTT at presentation should be referred to the
Specialist Diabetic/Obstetric Team to optimise their diabetic
control [49].
6. Termination of pregnancy
6.1. Background
Figures for the frequency of termination of pregnancy in
women with CF are difficult to determine. A UK multicentre
study between 1977 and 1996 reported that 19% of pregnancies
ended in therapeutic abortions [50], however none were
recorded by the UK CF Database 2001 [51]. A confidential
questionnaire in a large UK centre revealed a surprisingly high
number of miscarriages and terminations of which the CF team
S10 F.P. Edenborough et al. / Journal of Cystic Fibrosis 7 (2008) S2–S32was unaware suggesting significant underreporting (Personal
communication, F Edenborough). Some women require termi-
nation on medical grounds due to the severity of their CF but
there is a lack of published data on the number and reasons for
termination on either medical or psychosocial grounds in CF.
6.2. Reasons for termination
Termination of pregnancy may be a social convenience for
an unwanted unplanned pregnancy or a major psychological
undertaking if a much wanted pregnancy requires termination
for medical reasons. Given the excellence of neonatal intensive
care and the facilities to support a woman with advanced CF
should she choose to continue with pregnancy, perhaps against
medical advice, guidelines for when to terminate pregnancy
must remain fluid. Further the criteria for terminating may be
different when considering likely foetal outcome rather than the
mothers since a very sick woman may have a successful
pregnancy in that the child survives even if the mother dies and
some patients may choose to carry on against the odds in order
to leave a lasting legacy of their own being.
6.3. Psychosocial indications for termination of pregnancy
Although legislation will vary within Europe, in the UK the
termination of a pregnancy for psychosocial reasons may be
carried out to “prevent serious injury to the mental health of the
pregnant woman”. Clearly in CF the mother's physical health
may also come into this decision, blurring the boundaries be-
tween termination for medical and psychosocial reasons. Where
the pregnancy is genuinely unwanted with little ambivalence the
emotional impact of this is likely to be less problematic. The
psychological impact of termination of pregnancy for both
psychosocial and medical reasons in the general population is
outlined in Section 6.4.
6.4. Medical indications for termination of pregnancy
6.4.1. Absolute contraindications to pregnancy
The only absolute contraindications appear to be pre-existing
pulmonary hypertension and cor pulmonale [52,53]. An FEV1
b60% [54,55] or even 70% [56] has been recommended as
necessary for successful pregnancy but this is not the same as
recommending termination if FEV1 is lower. An FVC b50% [53]
has been recommended as an indication for termination but
successful pregnancies have occurred with FEV1 b40% and FVC
b50% [54,55,50,57]. Poor lung function is usually associated
with hypoxia either during exertion, at night or continuously and
this may lead to foetal growth retardation and prematurity. If
hypoxia is not correctable without acidosis (itself unusual in
pregnancy) this should also be regarded as a contraindication.
6.4.2. Relative contraindications to pregnancy
6.4.2.1. Nutrition. Poor nutrition has long been recognised as
a marker of poor prognosis. In the UK study [50], of eight
women with a BMI of b18 kg/m2 (b85% Ideal Body Weight)five miscarried and three delivered prematurely. Nonetheless
aggressive nutritional therapy may improve this.
6.4.2.2. Diabetes. Diabetes complicates normal pregnancy
and would be expected to adversely affect pregnancy in CF but
in the US study [57] even diabetes was associated with a better
outcome compared with non-pregnant diabetics and, as stated
earlier, the UK study [50] of 48 pregnancies included seven
diabetics who did not appear to have a significantly worse
outcome although there was a trend to more premature births
and the need for caesarean section.
6.4.2.3. Microbiological issues. Burkholderia cepacia com-
plex has also been suggested as a relative contraindication [58].
Three women in the UK study [50] grew the organism, all lost
weight and required antibiotic therapy, two delivered prematurely
and one had a termination for foetal anomalies. Two other studies
have reported poor outcomes in B cepacia complex infection.
The first [58] commenced a pregnancy with FEV1 31% and
delivered an infant at 25 weeks by emergency caesarean section
and died on the 10th post-operative day. The second [59] had a
pre-pregnant FEV1 of 73% but had recurrent infective exacer-
bations and lost 7 kg inweight during the pregnancy, delivering at
29 weeks, but lost further weight and lung function to FEV1 22%
and died six months post-partum. It is likely that B. cenocepacia
andB. multivorans (genomovars III and II respectively) represent
the greatest risk and any patient with these organisms should be
counselled about the risk of rapid decline in pregnancy.
6.4.2.4. Liver disease. Significant liver disease may also be a
relative contraindication but there is no information in the CF
literature to guide us.
6.4.3. Comment
Rate of decline may be more important than absolute lung
function. Awell nourished woman with poor lung function may
fare less well than a slim woman with good lungs whilst a
patient with a stable FEV1 of 50% may represent less risk than a
woman with FEV1 80% with Burkholderia spp. and diabetes
etc. Clinicians must weigh up the relative potential for the
successful management of each complication and add the
residual risk to their baseline for counselling a patient who
wants a pregnancy but may need to consider a termination.
6.5. Obstetric indications for termination of pregnancy
If a serious foetal anomaly is discovered in the first or second
trimester of pregnancy and if after due counselling, it is the wish
of the woman and her partner that the pregnancy be terminated,
the method of termination should be no different to those used
for someone without CF.
6.6. Methods of termination of pregnancy
6.6.1. Surgical termination of pregnancy
Surgical termination can be performed under regional or
general anaesthesia using cervical priming agents such as are
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reduce the risk of cervical damage and uterine perforation [60].
6.6.2. Medical termination of pregnancy
There is little in the CF literature to guide us regarding
medical termination, but Edenborough [61] reported two cases
with FEV1 of 22% and 41%, BMI 18.6 kg/m
2 and 21.5 kg/m2
and 31 and 60 days of amenorrhoea respectively. Both were
relatively well at presentation, both received oral antibiotics and
underwent termination with mifepristone and gemeprost
according to recommended guidelines. Both required pethidine
for analgesia but neither experienced any complications. No CF
related adverse effects from the drugs were experienced.
Medical termination can be performed at any gestation but
usually before 22 weeks. The regimen recommended is;
Mifepristone 600 mg orally followed 36 to 48 hours later by
gemeprost 1 mg vaginally every three hours to a maximum
of five pessaries. Usually only one pessary is required in
early pregnancy (before 12 weeks gestation).
An alternative and less expensive regimen is;
Mifepristone 200 mg followed 36–48 hours later by
misoprostol 800 mcg vaginally then misoprostol 400 mcg
orally three hourly to a maximum four doses.
The use of misoprostol tablets for abortion procedures by the
vaginal route constitutes an unlicensed indication and an
unlicensed route of administration. However, the EU Pharma-
ceutical Directive 89/341/EEC specifically permits doctors to
use ‘licensed medicines for indications or in doses or by routes
of administration outside the recommendations given in the
licence’. This is endorsed in recent articles in Drug and
Therapeutics Bulletin [62] and Prescribers' Journal [63].
6.7. Anaesthesia for termination of pregnancy
The advantages of general versus regional anaesthesia will
need to be carefully considered for each patient. General
anaesthesia is avoided where possible to minimise the risk to the
CF chest.
6.8. Medical care during termination of pregnancy
Whatever method of termination is agreed upon, respiratory
status should be optimised prior to the procedure. Antibiotics
are usually given before and after general or spinal anaesthesia
and analgesia, physiotherapy and early mobilisation are im-
portant post-operatively.
6.8.1. Physiotherapy during and after termination
The principle considerations are as for the time of delivery
(see Section 9.4). If general anaesthesia is chosen, passive ACT
can be carried out with positioning as required during the
anaesthetic (see Section 9.4.2). ACT and physical mobilisation
should be encouraged as soon after the procedure as possible.6.9. Psychological impact of termination of pregnancy
6.9.1. Spontaneous miscarriage
Little is known about miscarriage or its impact in CF. The
usual sense of loss and grief may be complicated by a sense of
limited opportunities and time to have a successful pregnancy
because of CF. Support from within the CF team may be
necessary because of these factors.
6.9.2. Termination for psychosocial reasons
Much research has been published on the after effects of
termination of pregnancy in women without CF. Most women
who have early termination of pregnancy for psychosocial
reasons do not appear to have lasting negative effects [64]. For
some the main emotion may be relief. For others there may be
more negative reactions such as short-term feelings of sadness
and guilt, whilst only a small minority go on to have more
lasting negative effects. Factors thought to influence this
outcome include the degree of ambivalence towards the event,
the perceived supportiveness of others and the degree of
psychological problems before the event. Routine support and
counselling offered pre- and post-termination of pregnancy (for
psychosocial reasons) might be sufficient for those with CF.
This may be provided by the usual agencies, although there may
be some additional issues for those with CF that the CF team
may be in the best position to discuss e.g. the role that CF may
have played in the decision to terminate pregnancy.
6.9.3. Termination for medical reasons
There is some evidence that termination for medical reasons
may be associated with long-term negative psychological effects.
A normal grief reaction combined with a sense of a burden of
responsibility, may lead to feelings of sadness for many years and
about 20%may remain angry, irritable and tearful, with feelings of
guilt and failure, two years on [64]. Research on women under-
going termination for foetal abnormalities suggested that
adjustment may be particularly difficult when the women are
young, where there were previous stresses and in cases involving
more ambivalence about the decision. There is no research in CF
but it may be hypothesised that women with CF who choose a
termination of a foetus known to have CF may experience partic-
ular distress or mixed emotions. Psychological reactions may also
be intense in women with CF who may require termination of a
desired and potentially healthy foetus for reasons of their own
health and psychological support should be available to these
women and their partners/families. Termination of pregnancy for
medical reasons may also have some impact on teams caring for
those women involved. Involvement of specialist colleagues, who
can for example advise on sensitive issues such as the potential
viewing and disposal of any products of pregnancy, can be useful.
7. Established pregnancy
7.1. Coordinating CF care
The support offered to a woman with CF throughout preg-
nancy should be proactive and encouraging. Struggling with a
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treatment regimens can be forgotten. Pregnant mothers can
become wary of medication and challenge the use of routine
therapies, often refusing some treatments. Alternatively, some
mothers-to-be adopt a more complementary approach to care
during pregnancy. The nurse must be aware of concerns and be
prepared to offer appropriate information, advice and support.
Whilst a degree of non-adherence to treatment regimens can
sometimes be acceptable, during pregnancy this is not accept-
able. Health status should be closely monitored with early and
aggressive intervention when necessary.
7.2. Maintaining well being
Fears and anxiety during pregnancy are common in healthy
women. These may include fear of abnormality in the unborn
child, fear of miscarriage or of not being able to cope with
parenthood. High levels of anxiety in pregnancy are known to
be associated with higher rates of postnatal depression [65]. It
might be expected that those with CF may have additional
worries. Whilst one study of parents with CF [66] indicated they
see themselves as ordinary parents with few extra concerns,
anxieties during pregnancy in CF have not been investigated.
Patients' well being should therefore be monitored to identify or
prevent potential problems in coping.
Psychological interventions to help cope with increased
treatment requirements and to encourage optimal adherence to
treatments may be indicated. Motivational interviewing has
been shown to impact on health behaviours outside the field of
CF and is increasingly being used in some CF settings [67], to
help patients manage their health and multiple treatments
effectively.
7.3. Optimising health and treatment
7.3.1. Management of lung function
During the first trimester, most women with or without CF
will feel subjectively breathless and care must be taken not to
assume this is physiological without looking for infection or
other causes as in the non-pregnant state. During the first six
months of pregnancy, the woman should be seen frequently in
clinic, perhaps monthly and two weekly in the final trimester or
more frequently as progress dictates. At each visit, physical
examination, measurement of oxygen saturation and pulmonary
function and weight should be performed and sputum should be
obtained.
7.3.2. Antibiotic use in pregnancy (see Appendix C)
Acute respiratory exacerbations may lead to continued loss
of lung function and hypoxia in addition to pyrexia and malaise
with loss of appetite. All are potentially harmful to the foetus
and should be treated in the usual way. β-lactams are thought
safe in pregnancy and thrice daily aminoglycosides at conven-
tional doses have not resulted in reports of hearing loss or renal
impairment in infants. Once daily tobramycin has been formally
tested in non-CF women in the second and third trimesters and
found to be safe and considered less likely to result in accumu-lation in the foetus with risk of oto- and nephrotoxicity reduced
despite higher peaks [68] There is no data on intravenous
colistin however in multiresistant organisms sensitive only to
colistin, this drug should be considered particularly in the latter
parts of pregnancy. Airway clearance therapies should be inten-
sified during antibiotic therapy, since a combined approach
therapy shows superior efficacy [69,70]. Ciprofloxacin use
during pregnancy in animals has been associated with cartilage
abnormalities, however, the drug has been widely used during
pregnancy in humans and at present no clear adverse effect has
been established [71], so that, if it is vital for the mother the drug
may be used.
7.3.3. Considerations for the physiotherapist
Physiological and mechanical changes encountered during
pregnancy affect the breathing pattern and advanced pregnancy
may lead to increased closing volume and even atelectasis. To
what extent the patient's degree of lung disease interacts with the
normal physiological changes at different stages of pregnancy is
highly individual. Some women may need help to differentiate
between the dyspnoea which occurs during respiratory exacer-
bations that require treatment and normal “physiological”
breathlessness of pregnancy, the management of which should
be taught early. Ideally the physiotherapist and the pregnant
woman should meet weekly to assess the effectiveness of the
physiotherapy regimen, monitor lung function, and the amount,
quality and colour of sputum, and to define musculoskeletal and
other problems related to the stage of pregnancy.
7.3.3.1. Nasal obstruction and upper airway clearance. Nasal
obstruction may occur during pregnancy causing mouth
breathing, snoring or even obstructive sleep apnoea in severe
case. Nose-breathing should be facilitated and encouraged
because it filters, warms and humidifies respired air. Further,
expiring through the nose gives a little resistance, and this
positive expiratory pressure (PEP) may make breathing more
comfortable for some with obstructive lung function. Effective
clearing of the nose is taught using saline spray, nasal lavage or
even suction and in extreme cases nasal surgery could be
considered. Topical nasal steroids or sympathomimetics are safe
and may be useful.
7.3.3.2. Effects of bronchodilators. Bronchodilators may be
counterproductive in advanced pregnancy as FRC decreases,
airways become more unstable and/or shunting occurs. If not
already performed reversibility tests with pulsoximetry should
be considered, including during late pregnancy when “breathing
mechanics” are significantly altered or if a “ticklish cough”
becomes problematic during ACT.
Physiological changes may require inhaled therapy to be
optimised by splitting each dosage into more than one
inspiration per dose actuation when using metered dose inhalers
(MDI) with a spacer or dry powder inhalers (DPI). If inhaling
via a nebuliser system deposition can be improved by varying
inspiratory flow rates and breath sizes between TLC and RVand
by inhaling in different positions to optimise regional ventila-
tion which may be of importance as the abdomen grows.
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physiological ACT strategy is described in Section 4.3.3.2
and adherence with and quality of treatment are regularly re-
viewed. As pregnancy advances FRC decreases but in parts of
the lungs a relatively increased closing volume may lead to
early airway closure and retained secretions, atelectasis or even
lobar collapse. Deep inspirations are essential supported by
correct use of PEP or non-invasive assisted ventilation by
biPAP. The abdominal muscles are progressively stretched
and can become separated down the midline (diastasis–rectus
abdominus). If mechanical pain or muscular herniation occurs, a
stabilizing binder or manual cough assistance is very useful.
7.3.3.4. Urinary incontinence. Pressure on the pelvic floor
from the foetus and coughing can lead to urinary incontinence
which affects quality of and adherence to ACT and is a social
handicap. Daily specific pelvic floor contraction exercises
should be taught and utilised during all airway clearance
manoeuvres from early pregnancy. Referral to an incontinence
specialist for further advice about hygiene and protection may
be required.
7.3.3.5. Gastro-oesophageal reflux (GOR). Some physiother-
apy manoeuvres may trigger or increase the frequency of GOR,
and if so alternative techniques should be used. Excessive
expiratory force especially at low lung volumes and in head
down and supine positions should be avoided as should ACT
soon after meals. The head of the bed may need to be raised on
bricks, and meals taken earlier in the evening. Nausea and
vomiting may be a complication making the ACT hard to do or
inefficient due to frequent interruptions. Adequate pharmaco-
logical treatment, anti-nausea-bands or transcutaneous electrical
neuromuscular stimulation (TENS) may be useful. These
problems should be brought to the attention of the team as
even in the absence of symptoms “silent reflux” can occur and
pharmacological treatment may be needed.
7.3.3.6. Hypoxia. If oxygen saturation falls to b90% during
ACT or physical exercise supplemental oxygen should be
administered to maintain oxygen saturations at around 92%.
Overnight pulse-oximetry should be considered to check for
nocturnal desaturation which may require nocturnal oxygen
supplementation.
7.3.3.7. Ventilatory failure (hypercarbia). Hypoventilation
due to advanced lung disease, acute exacerbation or respiratory
muscle insufficiency may require non-invasive assisted venti-
lation during ACT, at rest or during sleep [72–74]. Pressure
settings may need to be altered as pregnancy advances.
7.3.3.8. Postural changes and physical exercise in pregnancy.
Softening of ligaments with low muscle tone, enlarging breasts
and abdomen with increasing weight, cause biomechanical
changes that affect posture and activity. Neck and back pain can
result from increased lumbar lordosis. Pubic symphysiolysis,
sacro-iliac joint and round ligament pain are oftenmost noticeable
when arising from bed in the morning, during physical activity,standing and walking. Mobility training for the thoracic cage,
spine and shoulders should be continued alongwith balancing and
strengthening exercises for all bigger muscles around the pelvis
and in the lower extremities to help stabilize the joints.
Maintaining exercise capacity by choice of activity, intensity
and duration is essential. In late pregnancy aerobic capacity can be
increased significantly by non-weight-bearing exercises such as
ergometer-cycling or swimming. Oxygen saturation should be
monitored during exercise in all patients and supplementation is
given if SaO2 b90%.
7.3.3.9. Constipation. Progesterone causes slowing in small
bowel activity and exaggerates problems of constipation and
DIOS in CF. Advice can be given relating to physical activity
and to a position on the toilet that may assist with efficient
bowel emptying.
7.3.3.10. Timing physiotherapy sessions. Different compo-
nents of the physiotherapy regime may need to be carried out
one or more times per day and the frequency, duration and
timing should be tailored to coincide with the times of day the
woman feels most well and fitted around her other activities
accordingly.
7.4. Management of nutrition (see Section 4.3.4)
An overall weight gain of 12.5 kg is considered normal for
pregnancy [75] and a weight gain of at least 11 kg has been
recommended for women with CF [76]. Low preconceptional
BMI is associated with a high risk of low birth weight babies
and therefore the Institute of Medicine has recommended a
weight gain for pregnancy based on the pre-pregnancy BMI
though not all agree [77].
• BMI of 19.8 kg/m2–26.0 kg/m2: weight gain of 11.5–
16.0 kg
• BMIb19.8 kg/m2: weight gain of 11.5–16.0 kg plus an
additional 1–2 kg.
The theoretical energy costs of pregnancy have been
estimated to be 80,000 kcal for a 60 kg woman [75,78]. The
recommended energy requirements for pregnancy vary from
200 kcal/day in the last trimester only [38] to 300 kcal/day [79]
and patients with poor nutrition and a low BMI prior to con-
ception may need even more energy. Women with inadequately
controlled malabsorption due to pancreatic insufficiency, and
increased energy loss may require even greater energy intake to
support adequate weight gain for pregnancy. Early reports
suggested that supplemental enteral tube feeding may be re-
quired to achieve the additional energy requirements in women
with CF [80].
7.4.1. Types of feeding
7.4.1.1. Enteral tube feeding in pregnancy. In those requiring
enteral tube feeding for the first time, it is best considered early
in pregnancy when it is best tolerated. The choice of route is the
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for short-term nutritional support and may be appropriate in
pregnancy. Gastrostomy feeding has become increasingly
popular due to ease of endoscopic tube placement and success-
ful jejunostomy feeding has also been reported [81] in CF.
In those females who already have a (fixed length) balloon
gastrostomy button it would appear prudent to revert to a
(variable length) percutaneous endoscopically placed gastro-
stomy tube to prevent the risk of losing access as the abdomen
swells during the pregnancy. Ultimately the choice of route will
be influenced by patient preference and tolerance, the stage of
the pregnancy, local experience and facilities, and the advice of
the gastroenterologist or surgeon.
Feeds are usually best tolerated as a continuous pump assisted
infusions rather than bolus feeds. Most patients tolerate whole
protein polymeric feeds with a high energy density; however if
not tolerated there may be theoretical and practical benefits from
using elemental or semi-elemental formulae. Enteral tube
feeding may precipitate hyperglycaemia requiring insulin ther-
apy in people with CF [82] and this may be more likely in
pregnancy when there is a degree of insulin resistance and
impaired glucose tolerance. The introduction of enteral tube
feeding should be closelymonitored to assess its effects on blood
glucose levels [26,49]. As pregnancy progresses intragastric
pressure increases due to uterine enlargement, which aggravate
gastro-oesophageal reflux and increase the risk of aspiration. To
reduce this risk the bed head should be raised, feed volumes and
rates carefully monitored and prokinetic agents considered.
7.4.1.2. Parenteral feeding. Rarely parenteral feeding may
need to be considered when enteral nutritional has been in-
sufficient to promote adequate weight gain. This is usually
reserved for extreme cases and the risks and benefits need to be
carefully assessed. The successful use of parenteral feeding in
pregnancy in a woman with CF has been reported [83].
7.4.2. Specific nutritional requirements (see Section 4.3.4)
7.4.2.1. Protein. The optimal protein requirement in preg-
nancy is unknown. In the UK, 6 g/day is recommended [38].
7.4.2.2. Iron. Iron deficiency is common in CF [84,85] and
females with CF may enter pregnancy with inadequate stores
and even healthy women with CF may not be able to meet the
metabolic demands of pregnancy by increased absorption,
mobilisation of maternal stores despite the cessation of
menstrual loss. In the UK there is no increase in the reference
nutrient intake for pregnancy [38] but in CF dietary advice
should be aimed at increasing dietary iron intake, optimising
absorption by increasing the intake of vitamin C and reducing
intake of foods that reduce bioavailability e.g., tannins. Iron
levels should be measured at 20 weeks and supplementation
considered if deficiency is developing.
7.4.2.3. Calcium and vitamin D. There is no consensus on
optimal daily calcium intake between the UK [38], European
[86] or North American guidelines [87,88]. There is no increasein recommended intake for calcium in pregnancy except in
adolescents [38,88].
It is recommended that all women should receive supple-
mentary vitamin D to achieve an intake of 10 mcg/day [38]
(400 IU), however it is likely that a supplemental dose greater
than 10 mcg/day is required to improve circulating levels of 25-
hydroxyvitamin D [40–43] and people with CF may need more
still and levels should be reviewed.
7.4.2.4. Folic acid. See Section 4.3.4.6.1.
7.4.2.5. Essential fatty acids and other nutrients. Essential
fatty acid (EFA) deficiency has been reported in healthy women
during pregnancy and lactation [89] and this may further
exacerbate the already deranged EFA status of women with CF
[90]. The effect of essential fatty acid supplementation in
pregnancy in CF has not been studied. Several recent review
articles also highlight the importance of other micronutrients in
pregnancy [91–93] but these are beyond the scope of this
document.
7.4.3. Other nutrition related problems
Due to hormonal and mechanical changes in pregnancy
gastro-oesophageal reflux, heartburn, nausea, vomiting and
constipation may occur more frequently and be more trouble-
some for women with CF [82,94].
7.4.3.1. Nausea and vomiting. Nausea, vomiting and “morn-
ing sickness” are most common in the first trimester. Re-
assurance is important as heightened anxiety will not help the
situation and whilst nutritional deficits should be minimised
there is time for these to be corrected. Practical nutritional
advice for morning sickness centres around eating dry bread or
biscuits before getting up in the morning, eating small carbo-
hydrate rich snacks every 2 to 3 h, avoiding drinking liquids at
meal times, avoiding large meals with highly spiced foods etc. If
symptoms are severe short-term treatment with cyclizine or
prochlorperazine may be appropriate.
7.4.3.2. Gastro-oesophageal reflux (GOR). GOR and heart-
burn is common in both CF and pregnancy. It is usually worse in
the third trimester due to decreased motility and increased
intragastric pressure. Small, frequent meals or snacks are
usually better tolerated than large meals and foods that trigger
symptoms should be avoided. Treatment with a H2-receptor
antagonist such as Ranitidine may be necessary. Vomiting with
coughing may increase in people with CF due to increased
intragastric pressure as the pregnancy progresses.
7.4.3.3. Constipation. The aetiology of constipation in preg-
nancy is complex but is probably due to decreased gut motility,
increased absorption of salt and water from the gastrointestinal
tract [95], decreased physical activity and dietary changes.
Constipation may be more common in women with CF and this
may precipitate distal intestinal obstruction syndrome in some.
Dietary advice should be individualised as whilst an increase in
fibre and fluid intake may be beneficial for some it may result in
12 RCOG Green Top Guideline No. 26.
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poor weight gain. An experienced CF Specialist Dietitian
should assess and advise the patient.
7.4.3.4. Other nutritional problems. Food aversions, cravings
and pica are well recognised in pregnancy. Changes in hormone
levels, gut motility and heightened sense of taste and smell have
all been suggested as causative factors [96]. There is no
evidence that they are any more common in women with CF.
7.4.4. Management of diabetes (see Section 4.3.5)
If the woman is not known to be diabetic an OGTT should be
performed as soon as possible, especially if pregnancy has
apparently caused a change in the patient's pre-pregnant health
status. If already diabetic, control should be optimised through
the choice of insulin regimen, with human insulins being
preferred over any oral hypoglycaemic agents.
7.4.5. Management of liver disease
To the authors' knowledge no report of pregnancy in CF has
had CF related liver disease (CFLD) as a major focus and it is
barely alluded to in case series. It is thus not known what effect
CFLD may have on the ability to become pregnant or to carry a
pregnancy. For the woman with CF with minor liver disease
there are no special recommendations but the liver function
should be monitored throughout pregnancy and potentially
hepatotoxic medication should be avoided if possible.
7.4.6. Frequency of review
As soon as pregnancy is diagnosed the woman with CF
should be seen monthly at the CF clinic by all the team mem-
bers, and possibly more frequently by the physiotherapist. In the
last trimester we recommend visits every other week. Obstetric
visits are outlined in Appendix F. Throughout both obstetric and
CF teams should work closely together.
8. Antenatal care
8.1. Antenatal obstetric care
Antenatal care is based on the premise that serial observa-
tions on a pregnant woman may identify risk factors early and
allow timely intervention to minimise any such risk. A sug-
gested schedule of antenatal care is outlined in Appendix F.
8.2. Antenatal anaesthetic care
Successful delivery of anaesthetic services requires meticu-
lous planning and coordination with obstetrician, midwife and
the CF team. The coordinating anaesthetist must ensure that the
necessary systems are in place to allow the Anaesthetic Plan to
be implemented including effective communication between all
obstetric anaesthetists and a mechanism for following the
patient's progress through the antenatal care pathway.
An introductory meeting between the pregnant woman and
an obstetric anaesthetist should be arranged soon after booking
and by 12–16/40 so the role of the obstetric anaesthetist can beexplained including possible options for delivery. A planning
meeting should be held at ∼26/40 and the anaesthetic plan
should be discussed with the CF team and disseminated. The CF
team should notify the anaesthetist of adverse factors including
low oxygen saturation, lung function, weight and diabetes and
the presence of pulmonary hypertension and in advanced lung
disease the requirement for assisted ventilation should be
considered.
8.2.1. Venous access
Although many patients will have a totally implantable
vascular access device (TIVAD), the flow rate is extremely
limited and the external device can become unpredictably dis-
placed or blocked. Separate peripheral venous access is recom-
mended and this should be discussed with the patient.
9. Delivery
9.1. Obstetric considerations
All reviews of pregnancies in women with CF have shown
that the majority end in spontaneous vaginal delivery of the
baby. Where there is evidence of maternal or foetal compromise
caesarean section is the delivery of choice, preferably with
spinal anaesthesia. Indications for operative vaginal delivery are
traditionally split into foetal or maternal.
The foetal indications are no different to those in non-CF
women but it may be judicious to shorten the second stage of
labour in women with severe CF to prevent prolonged Valsalva
manoeuvres. Forceps and vacuum extraction are associated with
different benefits and risks12 but may be used if appropriate to
the clinical circumstances.
9.2. Anaesthetic considerations
Anaesthetic considerations in CF have been discussed
elsewhere [97,98] and special anaesthetic problems in preg-
nancy in CF described around case reports [58,102]. The pri-
mary concerns are severe respiratory disease and infection,
gastro-oesophageal reflux and diabetes. Adequate early anal-
gesia and flexible post-partum analgesia to permit physiother-
apy and early mobilisation is advantageous.
9.2.1. Labour analgesia
Antenatal preparation and psychological methods of pain
management are recommended. Low dose epidural analgesia is
specifically recommended as it provides high quality pain relief
and reduces cardiovascular and respiratory work with the
flexibility to convert to epidural anaesthesia for assisted vaginal
delivery or caesarean section. Opioid analgesia is less effective
and nitrous oxide may be complicated by gas trapping and
barotrauma. Use of either should be reviewed in the light of the
severity of the patients CF.
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Regional techniques are recommended. Combined spinal
epidural or pure epidural anaesthesia offer the advantage of
control of block height and opportunity for post-operative
epidural analgesia (which facilitates early physiotherapy) but
the patient may require careful positioning if they cannot lie flat.
General anaesthesia may be required in the severely compro-
mised patient. Close liaison with intensivists is recommended.
9.2.3. Obstetric High Dependency Unit
Peripartum care should usually be delivered in the Obstetric
High Dependency Unit and the patients should be familiar with
this plan to minimise anxiety.
9.3. Indications for premature delivery
Whatever the indications for planned early delivery before
37 weeks gestation it is essential that the mother receives
antenatal steroids at some stage before 34 weeks gestation as
this has been shown to reduce the incidence of respiratory
distress syndrome in premature babies. The dose of steroids
used should be Betamethasone 12 mg given intramuscularly
(IM) followed 12 h later by a further 12 mg dose IM. A delay of
24 h between doses is acceptable if circumstances preclude a
12 h gap.
9.3.1. Foetal indications
Foetal indications for early delivery include signs of pla-
cental insufficiency namely foetal growth restriction, or acute
foetal compromise. Growth is measured by serial ultrasound
measurements and measurement of symphysial–fundal height
which are plotted on standardised growth charts. Foetal well-
being and the identification of foetal compromise are usually by
means of Doppler studies on the foetal circulation combined
with non-stress cardiotocography of the foetal heart.
Having identified the at-risk foetus the dilemma for the
obstetric team is which mode of delivery will produce the best
outcome for mother and baby. Attempts at induction of labour
and vaginal delivery which may be best for the mother will need
to be weighed against the risk of aggravating acute foetal
distress by the methods of induction and the necessity of an
emergency caesarean section, with all its attendant risks. A
planned caesarean section may be the best option in the delivery
of the at-risk foetus in this particular group of patients.
9.3.2. Maternal obstetric indications
As most women will be primegavidas the obstetric indica-
tions for delivery will usually be the common obstetric com-
plications of a first pregnancy including pre-eclampsia, foetal
growth restriction and obstetric cholestasis. The identification
of these problems and the planned early delivery of the baby to
alleviate them should follow established obstetric protocols.1313 The Royal College of Obstetricians and Gynecologists publish Green Top
Guidelines for the Management of Common Obstetric Problems and these can
be accessed via the RCOG website. www.rcog.org.uk.9.3.3. Maternal medical indications
Generally speaking, in pregnancy in healthy women, the
concerns of the foetus should dominate the discussion around
the indication for planned premature delivery, especially prior to
37 weeks when the risks to the foetus from the complications of
prematurity increase. However in CF a high proportion (26%
[99]–46% [50]) of pregnancies end up having spontaneous or
therapeutic preterm deliveries and the usual indication is failing
maternal health.
9.3.3.1. Failing lung function and hypoxia. In the UK study
[50] including 48 live births (to 42 women), 22 (20) delivered
prematurely, 10 by caesarean section, all performed urgently
due to deteriorating pulmonary function including two pneumo-
thoraces. Of those women who delivered prematurely due to
spontaneous labour only six out of 11 required assistance of
forceps or Ventouse extraction. Retrospective review of the
women who delivered prematurely confirmed their pre-preg-
nant lung function to be significantly lower than those deliv-
ering at term i.e. they were sicker at the onset of their pregnancy.
Persisting hypoxia, the development of ankle swelling or
headaches in the context of poor lung function are grave signs
and whilst support with oxygen and non-invasive ventilation
has been described [72] the prognosis for mother and, if very
early in pregnancy, the infant is poor.
9.3.3.2. Nutrition and diabetes. Poor weight gain, poorly con-
trolled diabetes (but not yet diabetes induced infant macrosomia
in CF), are sometimes cited as contributing factors to planned
premature delivery but these generally coexist with deteriorating
pulmonary function.
9.4. Physiotherapy considerations peripartum
9.4.1. Conscious delivery
A degree of physiological hyperventilation is normal
throughout pregnancy. During labour hyperventilation increases
further and in health still exceeds the increased oxygen demand
of labour and delivery. However, pain and anxiety can lead to
rapid shallow breathing and a decrease in alveolar gas exchange
and hypoxia, hypercarbia and respiratory acidosis occur more
readily in women with more severe pulmonary symptoms [100].
Adequate analgesia reduces pain, fear and fatigue and oxygen
supplementation should be used if there are desaturations. If
labour is prolonged and the lung function is poor, the woman
may need assistance with evacuating mucus between labour
pains. Bronchodilators should be given during labour if
beneficial [101]. During ACT or between contractions the use
of positive expiratory pressure (PEP) or biPAP may facilitate
large tidal volumes and reduced respiratory rate to mobilise
secretions and improve gas exchange. Women with copious
secretions or borderline respiratory failure should be famil-
iarised with biPAP before delivery [72,102].
Regional anaesthesia is preferred for natural birth and for
caesarean section. Inhalation therapy and ACTshould be carried
out before anaesthesia [102]. If the woman is thin, has
poor muscle tone, is tiring or if the abdominals are separated
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bearing-down during contractions to aid delivery and with
assisted coughing.
9.4.2. Delivery under general anaesthesia
If needed ACT can be carried out before and after
anaesthesia, before the section and before awakening. A large
bore oral endotracheal tube may be preferred to allow use of
large bore suction catheters for sputum clearance. Loosening,
transporting and evacuating secretions can be performed by
repeated cycles of low flow bagging to TLC interspersed with
thoracic compression to RV. After 3–5 cycles (depending on
amounts of secretions) suction is added whilst compressing to
RV Tenacious secretions can be loosened by instillation of 5 ml
isotonic saline during the bagging and thoracic compression
manoeuvres. The final manoeuvre should be to repeat bagging
to TLC leaving the woman with as much opened airways as
possible.
10. Pregnancy post-transplantation
10.1. Historical background
It is almost 50 years since the first child was born to a female
transplant recipient. Data are most abundant following kidney
transplantation. The first two pregnancies after heart–lung
transplantation (for primary pulmonary hypertension and
Eisenmenger's syndrome) were reported in 1989. The women
conceived approximately two years after transplantation and
delivered healthy babies, one at 34 weeks gestation, the other at
term. No further follow-up has been given on the mothers' or
babies' health [103]. Since this early report, 40 pregnancies and
their outcomes have been reported in heart–lung, bilateral lung
and single lung transplant recipients. Only a handful of
pregnancies have been reported in CF lung transplant recipients
[104–107]. These cases have most recently been summarised
by Gyi [107].
Time from transplantation to conception was in general two
years, but pregnancies as early as six months [106] and as late as
48 months [108] after transplantation have been reported. In the
40 patients reported to date, 40 pregnancies gave rise to 23 live
births of which ten were premature. There have been no
neonatal deaths or major malformations. Unfortunately, there
is no long-term follow-up of these children. In most cases,
follow-up is either not available or limited to the first year. Only
Gertner [104], Baron [105] and Gyi [107] provide follow-up for
a total of 11 children over several years.
Pregnancies in CF lung transplant recipients are considered
high-risk pregnancies and should be carefully planned and
followed by a lung transplant physician familiar with CF as well
as an obstetrician. Most lung transplant recipients will even-
tually develop some degree of hypertension and renal dys-
function because of the immunosuppressive medication [109].
The incidence of hypertension and pre-eclampsia in pregnant
lung transplant recipients reported by Armenti [110] were 50%
and 13%, respectively. Because impaired glucose tolerance is
common in CF, transplant recipients may have a higher pro-pensity to develop gestational diabetes but this has not been
formally reported.
10.1.1. Outcomes of the foetus in transplanted mothers
Up to 50% of infants born to transplant recipients are pre-
mature and 20% have intrauterine growth restriction [111]. The
consequences of prematurity (particularly birth b34 weeks
gestation) include neonatal death, long-term morbidity and low
intellectual quotients. Low birth weight may predispose to
further adult morbidities. Transmission of CMV to the foetus
due to CMV reactivation in the mother has been reported in
renal and liver transplant recipients and represents a real risk in
pregnant lung transplant recipients, especially if there has been
a CMV mismatch between the mother and her donor [112,113].
At present there has been no case of congenitally transmitted
toxoplasmosis in transplant recipients.
10.2. Counselling
10.2.1. Genetic counselling
See Section 4.2.1.
10.2.2. Psychosocial issues (see Section 4.2.2)
Pregnancy in CF after lung transplantation remains uncom-
mon and there is no specific literature on the psychological
issues involved. Women who have undergone transplantation
may feel that with a new lease of life comes the opportunity to
start a family. However, the issues involved in making such a
decision may be even more complex than usual in CF, as there
will be additional risk factors for bothmother and child. It is even
more important that time be given to discussing and planning
any pregnancy carefully. Recent survival figures (56% at four
years post-transplant) [114] suggest that the issue of themother's
future mortality will be more pertinent for those post-transplant
and lead to difficult discussions between patients and teams.
Transplant can also bring emotional challenges of its own and
there may be significant rates of depression and anxiety in
patients with CF following transplantation [115]. Support of
those women with CF considering pregnancy may be compli-
cated by the logistics of their delivery of care, which will prob-
ably now come from more than one centre, depending on local
arrangements. This may make it more challenging to ensure
good communication and continuity in sensitive discussions
between women with CF and their health care professionals.
10.3. Optimising preconceptional health and treatment
10.3.1. Contraception
Successful lung transplantation may rapidly restore fertility
in female recipients. Thus, post-transplantation contraception
and fertility issues should probably be discussed with all women
of reproductive age prior to transplantation. Hormonal contra-
ception seems to be safe in transplant recipients as long as
hypertension is well controlled. In contrast, immunosuppressive
agents probably decrease the effectiveness of intrauterine
devices and immunocompromised subjects using these devices
have increased risk for local infection [111].
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Although there is no formal trial data, it appears that the risk
of acute and chronic rejection may be increased during preg-
nancy and immediately post-partum. It is possible that the
immunosuppessive requirements may increase during pregnan-
cy and levels should be checked regularly. The optimum reg-
imen remains unknown [111] but there is extensive experience
with cyclosporin. The consequences of hyperemesis gravi-
darum may lead to decreased absorption of medications [116] or
promote aspiration. Potential graft dysfunction is difficult to
investigate because fluoroscopy for transbronchial biopsies
should be avoided though performing biopsies blind is possible.
10.3.2.1. Immunosuppressive drugs and the foetus. Immuno-
suppressants cross the placenta to varying degrees. No definite
pattern of congenital malformations has been associated with the
use of calcineurin inhibitors (cyclosporin, tacrolimus), azathio-
prine or steroids. Extensive experience with cyclosporin in other
conditions has not revealed a tendancy to foetal malformation.
Classification of other drugs is as follows: Steroids have no
proven risk in humans, risks from cyclosporine A and tacrolimus
are unclear whilst there is conflicting evidence for mycophenolate
mofetil concerning the risk of major malformations [117,118].
The newer drugs sirolimus and everolimus are clearly contra-
indicated during pregnancy because of their anti-proliferative
effects. There is no information at all available on reproductive
outcomes for daclizumab, orthoclone OKT3, anti-thymocyte
globulin, rapamycin and anti-IL-2-receptor antibodies.
10.3.3. Considerations for the physiotherapist
Healthy transplanted lungs require little physiotherapy input
but the physiotherapist will have a role in monitoring for signs of
possible infection or rejection episodes, andmaintaining posture,
mobility, pelvic floor and physical strength as before. It should be
remembered that the patient still has their own upper airways and
nasal obstruction or sinus infections may occur. Lungs with
obliterative bronchiolitis may become infected with Pseudomo-
nas and productive of sputum inwhich case all the physiotherapy
considerations in Sections 4.3.3 and 7.3.3 will apply.
10.3.4. Optimising nutrition (see Section 4.3.4)
A recent Consensus Conference made recommendations for
advising transplant recipients about pregnancy and their
subsequent management [111]. There is little or nothing in the
literature describing the nutritional management of this group of
patients. Nutritional interventions and advice will centre on
reinforcing advice about foods that effect immunosuppressive
drugs e.g., grapefruit juice [119] and food safety issues.
Preconceptional nutritional assessment and management will
be similar to that above.
10.3.4.1. Optimising nutritional status and maximising
intake. Although the nutritional problems seen in CF prior to
transplant are likely to be much improved it remains important to
optimise intake, ensure adequate weight gain during pregnancy,
screen for vitamin deficiencies and correct themwith supplements
including folic acid as early in pregnancy as possible andpreferably as part of preconceptional planning. Only areas of
specific concern to the transplantedmotherwill be discussed here.
10.3.4.2. Vitamin A. High circulating plasma vitamin A (and
vitamin E) levels have been reported in patients with CF
following lung transplantation [120] though the potential effect
on a foetus is unknown in pregnancy in CF. Serum levels of
vitamin A should be checked in the preconceptional period and
it may be necessary to stop supplementation. If levels are low
and can be monitored [121] doses of supplemental vitamin A
should not exceed 10,000 IU/day [35].
10.3.4.3. Vitamin D. Osteoporosis is common in patients with
CF [122,123] especially following lung transplantation [124].
Chronic corticosteroid therapy after transplantation impairs
calcium absorption and increases urinary calcium excretion and
may induce further loss of bone mineral density [125].
Optimising vitamin D and calcium intake is essential. Because
vitamin A levels may be increased after transplantation,
combined vitamins A+D preparations may need to be stopped.
A vitamin D supplement will be needed so that the
recommended intake of 10 mcg/day (400 IU) of vitamin D
[38] or higher may be safely achieved [40–43].
10.3.5. Optimising diabetes care (see Section 4.3.5)
Diabetes may be more common in the post-transplant patient
due to tacrolimus based immunosuppression and increased
corticosteroid use [126]. Assessment of diabetic status by oral
glucose tolerance test in the preconceptional period is essential.
Women with established diabetes or those with known impaired
glucose tolerance should be referred to the Specialist Diabetic/
Obstetric Team to optimise their diabetic control [49].
10.4. Summary
At present there are very little firm data on pregnancy after lung
transplantation and even less data on pregnancy in CF lung
transplant recipients. However, it appears that pregnancies after
lung transplantation are high-risk, probably for the mother, but
certainly for the foetus. The optimal timing from transplantation to
pregnancy is unknown but is probably beyond two years. Medical
advice given to a lung transplant patient concerning a pregnancy is
generally based on the guidelines, which have been developed for
renal transplant patients, without taking into account potential
organ-specific risks. Patients with ongoing, recurrent, or severe
acute rejection episodes or thosewho already present with progres-
sive bronchiolitis obliterans syndrome should probably be advised
against pregnancy. Co-morbid factors that might influence preg-
nancy outcome have to be taken into account, especially hyper-
tension, renal dysfunction, and CF or transplant related diabetes.
11. The postnatal period
11.1. Coordinating care for the new mum
For any newmother the first few days, weeks and months with
a newborn baby are exhausting, frightening and exhilarating.
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partner and grandparents should consider taking time to be with
the new mother as help and support is vital to prevent a
deterioration in her health particularly if treatment regimens
become secondary to the demands of a newborn.
New mothers with CF need advice about making time to rest
by getting as much help as possible for as long as possible and
finding ways to overcome practical obstacles e.g. a noisy
nebuliser waking the baby should not mean stopping all
nebuliser therapy. CF treatment should not be neglected, nutri-
tion and hydration are especially important if breast feeding and
early and aggressive treatment for chest infections is key and
can be made less onerous by taking advantage of CF homecare
support.
The CF team can support the new mother during this time by
careful planning of outpatient appointments, providing CF
Homecare, and telephone access. Often the partner or family
will also need support during this time and referral to the
local midwife or health visitor can provide other sources of
assistance.
11.2. Psychosocial issues
11.2.1. Postnatal depression
Significant psychological difficulties are experienced by
some women after the birth of a child, with postnatal
depression seen in 10–20% [65], usually arising within three
months of birth. Feelings of sadness, guilt, worthlessness and
anxiety, thoughts about suicide and death, difficulties in
concentration and decision making, disturbances of sleep,
appetite, levels of interest and energy are seen. The etiology is
unclear but vulnerability factors (e.g. personality, stress, lack of
perceived support, previous depression and mood problems
during pregnancy) combined with hormonal changes and
precipitating stresses make it more likely. Usual treatment
approaches include antidepressant medication and cognitive
behavioural therapy [65]. Rates of postnatal depression in
women with CF are not known but appropriate screening and
early intervention should be considered, either in primary care
or by the CF team.
11.2.2. Other issues
New mothers with CF may experience a range of difficult
emotions. The future probably tends to become more real for
most new parents and normal thoughts about what would
happen to a child in the face of parental illness or death may be
heightened in those affected by CF. However in one study [66]
parents with CF reported little worry about the impact of CF
upon their children and required no extra support with these
issues.
11.2.3. Balancing self care and care of a child
Having a child may have both positive and negative effects
on adherence to treatment. For some mothers, the presence of
the child will act as a powerful motivator to stay well. For
others, the demands of their own treatment are subverted by the
needs of a baby or toddler and the health of the mother maysuffer as a result. The partner must be involved in all aspects of
daily life including treatment, taking care of the baby/toddler
and household management.
11.3. Optimising health and treatment
After delivery full care should be instigated as soon as
possible with consideration to restarting any medication omitted
during the pregnancy unless breast feeding is being considered.
Epidural/spinal anaesthesia if used during delivery can be left in
situ to allow early respiratory physiotherapy. Some women with
steroid responsive airway disease may deteriorate after delivery
when cortisol levels normalize and inhalation therapy may need
to be modified. If antibiotics were not used prior to delivery they
should be considered (especially after general anaesthetic) early
in the post-partum period. Insulin regimens may need to be
tailored following careful monitoring of blood glucose and
optimal feeding. Nutritional supplementation should be
reviewed particularly if breast feeding is being considered.
Review should be frequent (end of IV's and after two weeks off
antibiotics as a minimum) though new mothers are often reluc-
tant to come to the CF centre given the added complication of
child care.
11.3.1. Contraception
Contraceptive advice should begin after delivery. Barrier
precautions should be taken in the early phase and oestrogen
containing contraceptives avoided if breast feeding as they may
inhibit lactation. Oral and depot progestogens are safe for
mother and baby from six weeks post-partum even if breast
feeding. Intrauterine copper containing devices may also be
used if breast feeding.
11.3.2. Chest physiotherapy for nursing mothers
In the uncomplicated delivery the woman requires rest and
time with the infant and partner and airway clearance can be
deferred. After prolonged vaginal delivery or a caesarean sec-
tion or in a woman with poor lung function, physical mobili-
sation and airway clearance should begin as soon as feasible.
Adequate pain relief is necessary to facilitate good quality
treatment and allow early mobilisation [73,101]. Oxygen
should be supplemented and manual assistance with cough
given if required. Ventilatory support should be considered if
there is respiratory muscle insufficiency or fatigue. Reminders
about training of pelvic floor contraction during all ACT, cough
and physical activity should continue. Stabilising binders may
help in the case of abdominal herniae or diastasis rectus
abdominus. Treatment sessions may take longer or need to
be divided into shorter sessions according to her physical
condition.
Ideally the physiotherapist should make a home visit to help
develop effective treatment routines around the mother's new
priorities. Time must be made for the mother so she can con-
centrate on her airway clearance and inhalation therapy away
from the baby. Physical activity is encouraged as soon as
possible. Exercise programmes can be developed to include play
with the child perhaps utilising its “weight” for strengthening
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tion must take account of her overall condition which may now
include swollen and aching mammary glands, unstable pelvic
floor and ligamental laxity. Lasting problems with abdominal
hernia(s) may be decreased with manual stabilisation during
ACTand coughing or by a stabilising binder. Surgical repair may
be necessary.
11.3.3. Nutrition and breast feeding
Breast feeding and breast milk have considerable benefits
for both the infant and the mother and successful breast
feeding in mothers with CF has been reported [127,128]. In a
Scandinavian study, 26 of 33 babies (79%) were breastfed,
however, the breast feeding was stopped before three months
[129]. Experience suggests many women with CF are unable
to maintain breast feeding for the recommended six months
but the consensus remains that women should be encouraged
to continue for as long as possible, possibly supplementing
breast with bottle feeding to allow her to rest unless it is clear
that she is unwilling or physically unable to sustain feeding
any longer.
The mother's choice of infant feeding method should be
respected and it is sensible to discuss infant feeding options
during pregnancy. Breast feeding is time consuming and poten-
tially exhausting and the mother will need to consider how she
will cope with this alongside her own medical treatments.
Breast feeding increases maternal nutritional requirements for
energy, calcium and many other minerals and vitamins [38]
and whilst not contraindicated in CF, each mother should be
individually assessed and advised taking into consideration
their individual preferences, health, clinical condition and
circumstances.
11.3.3.1. Composition of breast milk in CF. Contrary to an
early report [130] breast milk from women with CF has
normal electrolyte and protein levels [131,132] however low
levels of the essential fatty acids linoleic and arachidonic
acid [133] and low cholesterol levels [134] have been
reported.
11.3.3.2. Energy and protein requirements. Various estimates
of the additional energy to support lactation have been made but
an additional intake of approx 500 kcal per day is suggested for
the healthy mother [38] which varies depending on the stage of
lactation and the need for weight loss post-partum [38]. The
additional protein requirement for lactation is approximately
11 g/day for the first six months [38]. It is essential that these
energy requirements can be achieved over and above the
increased nutritional requirements associated with the mothers
CF. Nutritional advice centres on achieving an increased energy
intake and will necessitate the use of dietary supplements and
tube feeding if it cannot be achieved through dietary means
alone.
11.3.3.3. Calcium. It is estimated that the calcium loss
through lactation is approximately 210 mg/day although to
some extent this may be offset by adaptation in calciumhomeostasis [135]. An intake of 1250 mg of calcium (an
increase of 550 mg/day) is recommended for lactation [38]. In
those who have not achieved maximum bone density i.e.,
young women and adolescents an intake of 1500 mg/day has
been suggested [136]. Milk and dairy products are a con-
centrated and well absorbed source of calcium. Encouraging
the consumption of milk and milk products such as cheese,
yoghurt and ice cream will help to achieve adequate cal-
cium intakes. However some people may require additional
supplements.
11.3.3.4. Vitamin D. Vitamin D supplementation to achieve
an intake of 10 mcg/day (400 IU) is recommended for all
women during lactation [38] though it has been suggested that
this level of supplementation is inadequate and work on de-
fining requirements and optimal dosage is needed [43]. Women
with CF will usually be taking supplemental vitamin D but low
or suboptimal levels are common [122,123,137], and additional
supplementation may be required during lactation, even in those
who are pancreatic sufficient.
11.3.3.5. Fluid balance. Lactating women need approximate-
ly 2 l of additional fluid to protect against dehydration. This is
especially important in CF where dehydration can contribute to
distal intestinal obstructive syndrome.
11.3.3.6. Medication and breast feeding (see AppendixC). Many
drugs are passed into the breast milk and certain medications
are contraindicated during pregnancy and lactation. If any
mother with CF chooses to breast feed, her medications should
be reviewed by a pharmacist and the benefit to the mother
weighed against potential harm to the infant from the drug
itself or from not being breast fed. A drug that is safe for use
during pregnancy may not be safe for the nursing infant and
vice versa. The transfer of medications into breast milk de-
pends on a concentration gradient that allows passive diffusion
of nonionized, non-protein-bound drugs. Medications that are
highly protein bound, that have large molecular weights or
that are poorly lipid-soluble tend not to enter the breast milk
in clinically important quantities. The nursing infant's drug
exposure depends on the drug's concentration in the breast
milk and the amount of breast milk consumed by the infant.
The safety of certain drugs also depends on the age of the
infant. Premature babies and infants less than one month of age
have a different capacity to absorb and excrete drugs than older
infants [138].
Strategies for choosing drugs for use in nursing mothers
include use of topical therapy when possible and use of drugs
known to be safe if given as treatment to infants of that age.
Drugs should be chosen that have the shortest half-life and
highest protein-binding ability, are poorly orally absorbed and
of low lipid solubility. Timing the dose just after a feed or
before the infant's longest sleep periods offer the greatest
chance for the mother to metabolise and eliminate the drug,
however the metabolites of some drugs may themselves harm
the child, so consultation with a pharmacist is required re-
garding all drugs during breast feeding. Commonly used drugs
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Appendix C.
11.3.3.6.1. Sources of information. The Department of
Child and Adolescent Health and Development of the WHO has
published a publication called “Breastfeeding and maternal
medication. Recommendations for Drugs in the Eleventh WHO
Model List of Essential Drugs” [139] which classifies drugs
suitability in breast feeding as follows.
1. Compatible with breastfeeding – no known or theoretical
contraindications for their use – considered safe.
2. Compatible with breastfeeding. Monitor infant for side-
effects — theoretical, or occasional mild side-effects. Use
but inform the mother about any possible side-effects, and if
side-effects do occur, stop giving the drug to the mother or
stop breastfeeding.
3. Avoid if possible. Monitor infant for side-effects — known
side-effects in infants. Use these drugs only when essen-
tial and no safer alternative is available. Allow the mother
to continue breastfeeding but give her clear instruc-
tions about observing the baby and arrange for frequent
follow-up. If side-effects occur, stop the drug or stop
breastfeeding.
4. Avoid if possible. May inhibit lactation — Avoid if possible
or if essential encourage baby to suckle more frequently or
supplement with formula milk.
5. Avoid — Potentially serious side-effects on the baby. Stop
breast feeding during treatment. There are very few drugs in
this category apart from anticancer drugs and radioactive
substances.
11.3.3.7. Breast feeding after transplantation. Definitive
recommendations for the post-transplant patient regarding
breast feeding are difficult however recent consensus opinion
is that breast feeding need not be viewed as absolutely con-
traindicated. The degree to which immunosuppressants appear
in breast milk is dependant on numerous factors [140–142]
which again will need to be reviewed by the CF and transplant
teams (see Appendix C).
11.4. The infant
The most common complication for the neonate is to be born
prematurely with a prematurity rate among women with CF of
around 25% [2,127]. Prematurely born babies are prone to
respiratory distress syndrome, sepsis, cerebral haemorrhage and
hypoglycaemia and may in addition have experienced growth
retardation and be small for their gestational age [129,143–
145]. All such babies should be managed in Special Care Baby
Units.
11.4.1. Glucose homeostasis
Maternal diabetes and gestational diabetes are common in
women with CF during pregnancy [127,129] and in these
circumstances infants have to be carefully followed both in
utero and after birth, particularly after caesarean section
[129] since hypoglycaemia, hyperglycaemia, susceptibility topulmonary infections [143] and other complications may occur
[146].
11.4.2. Genetics in the child
All children of women with CF will be carriers, and
occasional children with CF have been born but this should be
less likely in the future with testing of the partner, preimplan-
tation diagnosis or amniocentesis/chorionic villus biopsy in
early pregnancy with the option of termination if the couple so
wish.
12. Follow-up
12.1. The mother
12.1.1. How to help make sure CF care does not suffer
It is predictable that routine CF care will suffer as new
parents will inevitably want to meet the demands of the baby
and the growing toddler first. The CF team should be aware that
health may deteriorate during this time and monitor lung
function, weight and overall health closely. The young mother
no longer has the luxury of time to dedicate to her own treat-
ment, there must therefore be frequent treatment reviews re-
ducing burden as much and as often as possible with the
involvement of the partner with prioritisation and tailoring
treatment to the ability of the family.
As children get older some parents involve them in the
treatment regimens such as helping with physiotherapy and
preparing nebuliser solutions. For some families this becomes a
helpful way of bringing the family together and helping the
child understand about their mother's CF. Other families keep
the children away from anything to do with CF as they feel that
it imposes the abnormal into their child's otherwise normal life.
There is neither a right nor wrong way of teaching children
about their mother's CF, however, it can be helpful if parents are
supported in explaining what is happening. The influence of
television and movies on children today often means that they
imagine far worse than reality, therefore honesty is to be
encouraged.
12.1.2. Longer term psychosocial issues
As the children of mothers with CF become older different
challenges may arise for the family. Whilst almost no research
has been conducted in this area, clinical experience suggests
that intervention may be required in several psychosocial areas
including coping with a parent's declining health, changes in
parental relationships as CF progresses and helping children
to understand and cope with their parents' illness as they grow
up.
Eventually mothers with CF will have to face declining
health, often whilst children are young and dependent. This can
complicate care at the end of life and specialist psychosocial
support may be necessary to address anticipatory grief in the
mother with CF and to help make plans/provision for children
after the mother's death. Some women will want to do this and
feel more in control if plans are made. For others this will be too
painful and will be actively avoided. In both cases expert
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CF team may also find such discussions with patients and their
families difficult and may themselves need support.
12.1.3. Time for daily routine physiotherapy
Finding time to perform daily inhalation therapy, ACT and
physical exercise become more challenging as being a parent
and looking after the family is balanced against personal health.
The patient must be reminded about the importance of
prioritising her own care. Practical evaluation and optimisation
of inhalation therapy and ACT and regular review of exercise
capacity and other musculoskeletal issues is essential and
should be carried out soon after delivery and reviewed regularly
as time goes. If desired, parts of the physical exercise
programme for a parent with an infant/toddler/child can be
modified by the physiotherapist to include the child as it grows.
Usually two treatment sessions per day are recommended, but
the content and timing is individualized.
12.2. The neonate
So far, no follow-up studies on infants born to mothers with
CF have been published. The effect of the parents' ill health or
death on a child born to a person with CF has never been
studied. Only one small study has included follow-up after
delivery [129] when 32 of 33 children were alive, growing well
and had reached normal developmental milestones at one year
of age. One child with a birth weight of 4.1 kg died age three
months from sudden infant death syndrome. No evidence of
CF was found in this child or in the 32 others included in the
study.
13. Prognosis for the mother
In the original case series [6] four of the five mothers in the
group who had all delivered prematurely and experienced a
decline in lung function during pregnancy died between five
days and 18 months after delivery. Conversely of the five whose
CF was little affected by pregnancy, no deaths were reported in
that time frame and two went on to have further pregnancies.
The first major review in 1980 [99] revealed ten of 100 mothers
(10%) died within six months and 15 (15%) within 24 months.
In the UK study [50] 12 women who had 17 pregnancies died
leaving 13 of 48 children in the study motherless, seven below
the age of five years and ten below the age of ten years. Median
(95% CI) survival after birth of first child for 41 mothers (10
deaths) was 11.9(8.6–16.3 years). When presented as 2% and
6% dying within six months and 24 months respectively it
compares favourably with the data of Cohen but still describes
the significant human tragedy of children left motherless at an
early age. Further data on long-term survival after pregnancy in
CF is lacking.
13.1. Does pregnancy affect survival of women with CF?
This question is moot. Four case-control studies have been
reported of 13 [147], 7 [59] and 33 [148] patients respectivelymatched to a variable degree for a variety of markers of
severity to non-pregnant controls. All three are flawed and
statistically underpowered. The first two concluded there was
no adverse effect of pregnancy. However, the first [147] despite
matching, had pregnant cases with better starting lung function
than non-pregnant controls but went on to have greater rates of
decline in all measures after delivery. In the second [59] the
pregnant group had significant decrease in both %FEV1 and %
FVC during pregnancy but the rate of decline was equal to
controls at one and two years post-partum. Group mean lung
function and hospitalisation rates were similar. However there
was a significant reduction in Brasfield radiographic score in
the pregnant group, one mother died six months post-partum
and in two cases there was a significant deterioration out of
keeping with their pre-pregnant status leading the authors to
conclude that certain individuals were adversely affected by
pregnancy.
In the third study, Edenborough et al. [50,148] matched 33
women who completed pregnancy and analysed them according
to term or premature (b37 weeks) delivery. As a group the
women who were pregnant showed no significant changes in
lung function during pregnancy or in lung function or weight up
to two years afterwards. However those who delivered pre-
maturely lost significant lung function compared to those who
delivered at term whilst the premature group's controls did not,
suggesting that women who had relatively impaired lung func-
tion went on to deliver prematurely fared less well than women
of equal severity who were not pregnant. The group delivering
prematurely differed from those delivering at term only in
having a significantly reduced pre-pregnant lung function (%
FEV1 81% vs. 59%; pb0.001). These data confirm lung
function to be the most significant predictor of pregnancy
outcome and suggest that pregnancy may directly affect women
with poor lung function leading to further decline impacting on
long-term prognosis. Conversely, those with good lung function
were unaffected by pregnancy.
The fourth, and by far the largest study to date is based on
women identified to be pregnant in 1990 by the North American
CF Foundation database [57]. A group of 680 women were
matched with 3327 non-pregnant controls by year of pregnancy
and observed for 12 years. From this group estimated median
(95% CI) 10 year survival post-successful pregnancy was 80
(73–85)% with a survival advantage for the pregnant women.
The data was analysed in several ways including severity
matching (rather than just year of pregnancy) and subgroups
analysis according to FEV1, presence of diabetes and by age
strata. Survival appeared to be no worse and probably better in
those who become pregnant with the exception of women age
b18 years.
Thus prognosis for mother with child appears to be closely
related to the severity of the mother's CF in the same way
that survival with CF is for the general CF population.
Statistically there may be little overall adverse effect of
pregnancy but almost all authors note that some women may
be adversely affected and these are usually those with more
advanced or poorly controlled disease. Every pregnancy in
CF should be regarded as potentially high risk for mother and
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caveat.
14. Summary
Pregnancy in CF is increasingly common and may occur
in relatively young fit women, those with impaired lung
function or nutrition and after transplantation. All members
of the usual Multidisciplinary CF team have a role to play in
educating and informing the woman of the potential impact
of pregnancy on her CF and of her CF on the pregnancy and
the foetus. The CF team will need to involve colleagues in
genetics, obstetrics, obstetric anaesthesia and midwifery and
good communication is essential. It is likely that the CF
Specialist Nurse will be the linchpin in the process of
coordination before, during and after pregnancy (see nursing
checklists Appendix A).
Ideally pregnancy should be planned in advance. Pre-
conceptional genetic counselling and assessment of the
practical and psychological preparedness of the woman for
pregnancy and the care of a potential future child is essential.
This should occur in parallel with optimisation of nutrition,
lung function and physical fitness, the three principle aspects
of preconceptional health that will impact on success or
otherwise of the pregnancy. Attention to detail of CF asso-
ciated complications (CFRD, liver disease, vitamin deficien-
cies etc) and review of medications are likely to further
improve chances of success.
Accidental pregnancy is not uncommon and may occur
unexpectedly in those even with the most impaired lung
function. Spontaneous miscarriage, termination for psychoso-
cial reasons or for medical reasons related to maternal health can
be fraught for patient and carers particularly in the latter case
where a much wanted, potentially healthy infant may be lost to
save the mother. Grief and sadness may be prolonged and anger
directed at the CF team in these circumstances or if the team
advises against a pregnancy when consulted due to maternal
health.
When pregnancy continues, regular review of lung function
and nutrition is essential and may require aggressive interven-
tion. The biggest single risk to the infant is likely to be the
mother's failing health and her treatment is paramount.
Flexibility of treatment regimens to accommodate the physi-
ological changes of pregnancy is necessary but should not
imply any relaxation of therapy. Early meetings with the
obstetrician and anaesthetist, perhaps including visiting the
delivery area and SCBU and meeting the midwives, and careful
planning of the type of anaesthesia and mode of delivery is
advisable.
The outcome for the infant is likely to be good with the
greatest risk being from prematurity, itself a result of the
mother's health whether pre- or post-transplant. The outcome
for the mother is dependent primarily on her lung health and
may be predictable from her pre-pregnant status, though
some women fare unexpectedly badly in pregnancy. Sadly
the reality is that any child is likely to lose their mother at a
relatively young age. Despite the pressures of a young familywomen must be encouraged to manage their treatment after
pregnancy just as thoroughly, if not more so, than before
pregnancy. The CF team will thus continue to play an
active role in the mothers care and may be privileged to share
joys of watching the children from such a pregnancy growing
up.
15. ContributorsTitle/role Name Country Email addressAssociate Professor
of Paediatrics,
ChairMarie
JohannessonSweden Marie.johannesson@mpa.seConsultant
Physician
Editor/
CoordinatorFrank
EdenboroughUK Frank.edenborough@sth.
nhs.ukObstetric
AnaesthetistMaria
BenhamUK Maria.
Benham@heartofengland.
nhs.ukMedical Geneticist Graziella
BorgoItaly Grazborg@yahoo.itConsultant
PhysicianChristiane
KnoopBelgium Cknoop@ulb.ac.beCF Physiotherapist Louise
LanneforsSweden Louise.lannefors@med.lu.seConsultant
ObstetricianBill
MackenzieUK Bill.
mackenzie@heartofengland.
nhs.ukConsultant Nurse Su Madge UK S.madge@rbht.nhs.uk
Clinical
Specialist
DietitianAlison
MortonUK Alison.morton@leedsth.
nhs.ukConsultant Clinical
PsychologistHelen
OxleyUK Helen.oxley@smtr.nhs.ukClinical
PharmacologistDaan
TouwNetherlands D.touw@ahz.nl16. Authorship
All authors were involved in submitting first drafts and
revisions to Dr Edenborough who as Coordinating Editor
constructed and edited the guidelines. All authors contri-
buted to the style and layout and final content of the
document.
Appendix A. Checklist for nursing management
Genetic testing
• Check genotype of mother and partner
• Nationality, ethnicity, family history of CF (including any
known mutations)
• State on request form that partner has CF and the couple are
trying to conceive
• Offer couple genetic counselling via appropriate sources
Liaison with obstetric team
• Ensure patient is referred to an obstetrician with experience
in CF
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options and plan of care
• Ensure close liaison/communication links with CF team and
general practitioner
• Provide 24 h contact information
• Maternity Department must have access to an Intensive Care
Unit and Neonatal Unit
Identify sources of ongoing support
• Discuss practical and psychological help post-delivery
(siblings, parents, friends)
• Consider nurseries/crèches/other childcare — does the baby
need to be registered before birth?
Maintain clinical care
• CF outpatients to coordinate with obstetric outpatients
• CF Homecare support where possible
• Planned admissions— especially before the expected date of
delivery
• Facilitate modifying drug, nutritional and physiotherapy
regimens to accommodate pregnancy
Talking to the couple about the reality of CF
• Discuss the possible deterioration of health status during
pregnancy
• Be proactive in recognising the increased need for treatment/
admissions
• Be prepared for a planned delivery (intravenous antibiotics)
Discuss the potential difficulties after pregnancy
• Provide guidelines/information about pregnancy and
delivery
• Acknowledge that it may be difficult to regain pre-pregnancy
health status
• Be prepared for emotional and physical exhaustion
• Accept that as new parents caring for baby may have priority
over mother's healthcare, help may be needed with this
• Help to balance increasing treatment demands/admissions
versus baby care
After delivery
• CF team to review treatment regimen and simplify where
possible
• Negotiate admissions/outpatient visits to fit in with child-
care, holidays etc.
• Consider/arrange to send child to nursery to provide a break
during the day
• Advise taking care with viral infections when their child
starts nursery
• Advise about how to talk to their child about CF as they grow
up
• Think about involving their child in CF careAppendix B. Psychosocial checklist for pregnancy in CF
CF and fertility
• Options if pregnancy cannot be achieved naturally
• Reaction to genetic information received and results of
partner screening etc
• Options if partner is a carrier of the CF gene
• Feelings about the possibility of having a child with CF
• Feelings about passing on the CF gene to all children and
implications of carrier status for them
• Circumstances when termination of pregnancy might be
considered
The health related implications of pregnancy
• Understanding potential impact of pregnancy and delivery
upon their own health
• Understanding the potential risks to an unborn child of CF
and treatment
• Fears/anxieties about pregnancy (CF and non-CF related)
• The best time in life to get pregnant in medical terms
• How to achieve optimal health pre-pregnancy and minimise
any possible risks of pregnancy i.e. behavioural changes to
maximise self care as recommended by the CF team
• Coping with possible increased requirements for treatment
and monitoring during and after pregnancy
• Implications of looking after a child whilst managing a
chronic illness and possible conflicts of interest
Social implications of pregnancy
• Financial implications for the family
• Reactions and support of significant others i.e. partners/
families
• Specific issues for healthy partners i.e. any risks of
pregnancy, impact on career and finances, childcare
arrangements and the possibility of becoming a lone parent
• The possibility of leaving a child motherless at an early age
• Other potential effects on a child of having a mother with CF
e.g. possible future role as a carer, impact of hospitalisations
of mother etc
• Emotions that might be generated by having a child and
parenting with the challenges of CF
After the birth
• Normalisation of usual postnatal reactions and mood
changes
• Screening and treatment for any occurrence of postnatal
depression
• Monitoring for other significant negative psychological
reactions to parenthood
• Help for any difficulties balancing treatment requirements/
good self care against the needs of a baby.
• Specific issues and support for those who have had a child
with CF
Appendix C
Drugs and their risks in pregnancy and at delivery
Drug/class Risk in first trimester Risk in second/third trimester Risk at delivery Recommendation Breast feeding
Acid inhibitory drugs
H2 antagonists Unknown no risk in
animal studies
Unknown No Unknown. Avoid if possible. PPI's preferred Avoid — present in milk, not known to
be harmful
Proton pump inhibitors Probably no risk No risk No Probably safe Compatible — low concentration in milk
Antibacterial drugs
Aminoglycosides
Gentamicin,
Tobramycin
(i.v., inhal.)
Associated with
nephrotoxicity in
the foetus
Associated with eighth cranial
nerve damage in the foetus but
not in CF literature
No I.V. Use only if risk of infection is
great. Once daily dosing preferred,
monitor levels
Compatible — low concentration,
low absorption (TOBI manufacturer
advises caution)
Inhal. Probably safe due to low absorption
from lung
Cephalosporins
Ceftazidime (and other
cephalosporins)
Probably no risk Probably no risk No Probably safe Compatible — low concentration in milk
Fluoroquinolones
Ciprofloxacin (and
other fluorquinolones)
Probably no risk Associated with cartilage
dyscrasias in animals
No Avoid during pregnancy, if a
fluoroquinolone is indicated, ciprofloxacin
should be chosen
Avoid — high concentrations in milk
Lincomycins
Clindamycin Probably no risk Probably no risk No Probably safe Caution — low concentration but
bloody diarrhoea in one infant
Macrolides
Erythromycin Probably no risk Probably no risk No Probably safe — use as first choice Compatible
Azithromycin Probably no risk Probably no risk No Probably safe — use above first Avoid — present in milk
Roxithromycin Probably no risk Probably no risk No Probably safe — use above first Avoid — no data
Clarithromycin Unknown Probably no risk No Avoid in first trimester Avoid — present in milk
Penicillins
Amoxicillin (and other
penicillins±clavulanate
or tazobactam)
Probably no risk Probably no risk No Probably safe Compatible — trace in milk,
beware hypersensitivity
Polymyxins
Colistin (i.v., inhal.) Probably no risk Probably no risk No I.V. Avoid if possible Caution — excreted in milk (however poorly
absorbed from gut)Inhal. Probably safe. Usually avoided esp in
2nd and 3rd trimesters
Rifamycins
Rifampicin (and other
rifamycins)
Rifampicin is associated
with foetal damage in
animals
Rifampicin is associated with risk of
bleeding by mother and neonate
when used in the last trimester
No Avoid during pregnancy, if necessary,
treatment with phytomenadione of
mother and neonate is indicated
Compatible — minimal present in milk
Sulphonamide/
trimethoprim
Sulphamethoxazole/
trimethoprim
Trimethoprim associated
with neural defects —
reduced by folinic acid
Sulphonamide use in the last
trimester is associated with icterus
of the neonate
Sulphonamide use at
delivery associated with
foetal haemolytic anaemia
Avoid during first and third trimester
and at delivery
Compatible in healthy term babies —
avoid if G6PD deficient or jaundiced
Trimethoprim Trimethoprim risk of neural
defects, reduced by folinic acid
Probably no risk if have normal
folate status
No Avoid during first trimester unless have normal
folate status. Short courses only
Compatible — low concentration in milk,
caution — long-term use.
(continued on next page)
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Appendix C (continued)
Drug/class Risk in first trimester Risk in second/third trimester Risk at delivery Recommendation Breast feeding
Tetracyclines
Doxycycline (and other
tetracyclines)
Probably no risk Tetracyclines are associated with
tooth and bone discolouration
Tetracyclines are associated
with tooth and bone
discolourations
Avoid during second and third trimesters
of pregnancy and at delivery should not be first
choice during 1st trimester (amoxicillin,
cephalexin or erythromycin)
Avoid — tooth discolouration
Carbapenems
Imipenem Foetal damage in animals Foetal damage in animals No Avoid in pregnancy Caution — present in milk, unlikely to be absorbed
Meropenem Unknown Unknown Unknown No information. Avoid in pregnancy but
consider risk benefit
Caution — present in milk but unlikely to
be absorbed
Other antibacterials
Chloramphenicol Probably no risk Use in the last trimester associated with
neonatal cyanosis and hypothermia
(grey-baby syndrome)
Use in the last trimester is
associated with neonatal
cyanosis and hypothermia
(grey-baby syndrome)
Avoid during the last trimester and at delivery Avoid — potential bone marrow toxicity
Metronidazole Unknown Probably no risk No Avoid during first trimester, avoid high-dose
regimes in later pregnancy very little data
Avoid — significant amounts in milk — stop
feeding for 12 h after each dose
Phosphomycin Unknown Unknown Unknown Avoid during pregnancy No information
Vancomycin Unknown — no evidence
of damage
Unknown, but there is no evidence
of foetal damage
No Avoid during pregnancy Compatible — excreted in milk but
absorption unlikely
Teicoplanin Unknown Unknown Unknown Avoid during pregnancy Compatible —present in milk poorly absorbed
Antihistamines
Cinnarizine (and
other antihistamines)
Probably no risk Probably no risk No Wide experience with older antihistamines:
class thought safe.
Avoid — no data
Antimycotic drugs
Fluconazole1,
Itraconazole1,
Voriconazole2,
Posaconazole2
All associated with foetal
damage in animals
All associated with foetal damage
in animals
No Avoid during pregnancy Avoid — excreted in milk1 or no data2
Amphoteracin Probably no risk Probably no risk No Probably no risk Avoid — no data
Nystatin Probably safe Probably safe No Probably safe Compatible
Antiviral drugs
Aciclovir, valciclovir Foetal damage in animals Used in second half of pregnancy to
avoid transfer of virus to foetus
No Avoid in first half of pregnancy Caution — aciclovir concentrated in milk, not
known to be harmful. Avoid valciclovir; no data
Ganciclovir Severe foetal damage
in animals
Severe foetal damage in animals Unknown Contraindicated Avoid — no data
Has been used without incident After transplant See reference
Blood glucose lowering drugs
Insulins/insulin
analogues
No risk No risk No Human insulins preferred, can be used
without risk
Compatible —reduce dose in lactation
Glibenclamide,
tolbutamide,
netaglinide,
repaglinide
Unknown Probably no risk Chance for neonatal
hypoglycaemia
Human insulins are preferred Caution — potential hypo-glycaemia in infant
Metformin Unknown Probably no risk but avoid —
insulin preferred
Neonatal hypoglycaemia Human insulins preferred Avoid — no data present in breast milk
Pioglitazone and
other thiazolidinediones
Foetal toxicity in animals Foetal toxicity in animals Chance for neonatal
hypoglycaemia
Human insulins are preferred Avoid — no data
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Bisphosphonates
Risedronate etc Foetal damage expected Foetal damage expected Unknown Contraindicated Avoid — no data
Cholelithiasis drugs
Ursodeoxycholic
acid (URSO)
Foetal damage in
animals and humans
Foetal damage in animals, no foetal
toxicity in man after the first trimester
No Avoid during the first trimester Avoid — no data
Contrast media aperients
Gastrografin No risk anticipated with
oral use
No risk anticipated with oral use No Probably no risk Compatible — not absorbed by mother
Corticosteroids
Systemic Foetal damage in animals,
not in humans.
Foetal damage in animals⁎, not in
humans. (⁎intrauterine growth
restriction in prolonged treatment)
No Systemic corticosteroids used for supplementation
therapy in adrenal insufficiency. Neonate should be
monitored for adrenal insufficiency
Compatible — monitor infant adrenal function if
maternal dose exceeds 40 mg prednisolone
Dermal corticosteroids Probably no risk with
normal use
Probably no risk with normal use No Class I and class II dermatocorticosteroids are
preferred. Use them intermittently. If class III/IV
dermatocorticosteroids are required, use them only
for a short time (max 1 week in the acute phase).
Compatible
Nasal, tracheal steroid
sprays and drops
Probably no risk with
normal use
Probably no risk with normal use No Can be used in pregnancy Compatible
Bronchodilator drugs
Sympathomimetics —
inhaled
Probably safe Probably safe No Probably safe, short acting
preparations preferred
Compatible
LABA — unknown LABA — unknown
Anticholinergic —
inhaled
Probably safe Probably safe No Ipratropium is preferred Caution — small amount in milk unlikely to
be harmful
Aminophylline/
Theophylline
Probably safe Probably safe Neonatal irritability and
apnoeas reported
Probably no risk Caution — present in milk: irritability in infants
reported. Give modified release preparations
after feeding
Pancreatic enzymes Probably no risk Probably no risk No Probably no risk Compatible.
Vitamins
Vitamin A In prophylactic doses
probably safe
In prophylactic doses probably safe No Doses of b10,000 IU/day are considered safe Compatible — at prophylactic dose.
Vitamin B group 1 Probably safe Probably safe except high doses of B6
associated with neonatal convulsions
No Probably safe. Compatible
High-dose B6 contraindicated
Vitamin C, E, K Probably safe Probably safe No Probably safe. High doses of vitamin C
may cause paradoxical neonatal deficiency.
Compatible
Vitamin D Probably safe in
prophylactic doses
Colecalciferol or ergocalciferol probably
safe in prophylactic doses
No Probably safe in prophylactic doses Compatible — at prophylactic dose: high doses
may cause hyper-calcaemia in infant
Post-transplant drugs
Cyclosporin Probably safe Probably safe Risk of reduced birth
weight/ prematurity
Probably no risk Avoid — present in milk
Tacrolimus Foetal damage in animal
studies
Foetal damage in animal studies Unknown Avoid during pregnancy (has been used
post-transplant without incident)
Avoid — present in milk
Azathioprine Small increase of foetal
malformations
Small risk of neonatal immuno and bone
marrow suppression, premature delivery
and low birth weight — monitor but do
not discontinue
No Avoid during pregnancy Avoid — stop breast feeding
Mycophenolate Foetal damage in animals,
possible malformations
in humans
Foetal damage in animals, possible
malformations in humans
Unknown Avoid in pregnancy Avoid — present in milk in animal studies
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General considerations
• Frequent evaluation of inhalation therapy, airway clearance
and physical exercise
• Gastro-oesophageal reflux
• Constipation
• Awareness of headaches and ankle swelling
• Home visits, especially after delivery
• Frequent telephone contacts
• Awareness of headaches and ankle swelling
• Liaison with Gynaecology/urine incontinence specialists
Optimisation of inhaled therapy
• Choosing devices according to patient needs, technique and
degree of lung disease
• Treatment strategies for different drugs with respect to
physiotherapy
• Bronchodilators (reversibility tests) for symptom relief or
adjuncts to other therapy
• Mucolytics
• Antibiotics
Optimisation of airway clearance therapy (ACT)
• Review timing, duration and frequency of regimen, efficacy
and adherence
• Continuing evaluation of chosen techniques, cough
control
• Assess nasal obstruction and need for upper airway clearance
• Consider adjuncts (e.g. flutter valve, PEP mask, assisted
ventilation)
• Oxygen supplementation during ACTor exercise if Sa02 b90%
Exercises
• Pelvic floor exercises as part of all physical activity and ACT
sessions
• Mobilisation of chest wall, upper spine and shoulder
girdle
• Strengthening of postural weight bearing muscles
• Training to improve work capacity
• Strategies for coping with ligamental laxity
• Strategies to cope with abdominal herniae and diastasis
rectus abdominus
Physiotherapy during labour
• Liaison with anaesthetist and obstetrician
• Consideration of airway clearance before and during
anaesthesia• Analgesia and early post-operative mobilisation
• Familiarise patient with oxygen supplements and non-in-
vasive ventilatory support as appropriate to condition prior to
deliveryPhysiotherapy in the neonatal period
• Review of techniques and re-establishing routines
• Time for mum to do treatment
• Pelvic floor exercises
• Chest wall mobility, posture and strengthening exercises
Appendix E. Nutritional checklist prior to conception/
early pregnancy
Preconceptional nutritional assessment and advice
• Assess weight, height, body mass index (BMI) and weight
history
• Dietary history/assessment
• Optimise nutritional status through staged nutritional
intervention
• Review pancreatic enzyme replacement therapy (PERT),
gastrointestinal symptoms and absorption
• Assess diabetic status by oral glucose tolerance test
• Optimise glycaemic control with conversion to insulin for
those on oral hypoglycaemic agents and referral to the
Specialist Diabetic/Obstetric Team
• Increase the understanding of the importance of folic acid
supplementation for the health and development of the
baby.
• Measure fasting plasma vitamins A, D and E and
review vitamin therapy (including non-prescription
items)
◦ Assess availability of vitamin A from the diet (especially if
oral calorie supplements or enteral tube feeds are being
incorporated).
◦ Continue vitamin A supplements if the level is normal at a
dose of less than 10,000 IU/day
◦ Reassure the patient that supplements are being pre-
scribed to prevent vitamin A deficiency which is also
teratogenic.
◦ Supplement vitamin D levels if low
◦ Commence vitamin D supplementation in pancreatic
sufficient females not routinely prescribed vitamin D
supplement
• Measure trace elements and supplement where required
• Increase awareness of food safety issues
• Encourage women to avoid alcohol if they are trying to
become pregnant
• Limit caffeine consumption to no more than 300 mg/day
(approximately four cups of coffee or equivalent).
Appendix F
Antenatal care framework for pregnant women with CF
Gestation (weeks) Carer Information Content of care Investigations
6–12 (may require
2 appointments)
Obstetrician Booking visit; screening options; pregnancy
complications (pre-eclampsia, diabetes, cholestasis)
Obtain medical, obstetric and social history; blood
pressure, urinalysis; Explain MSSU, weight/weight
gain (Wt/gain) provide written information
Age
Social problems
Midwife Calculate gestation
12–14 Sonographer Blood tests, obtain consent; explain growth chart;
parent education classes. Introductory meeting
with anaesthetist
Dating scan, Assess BMI and Wt/gain collect MSSU Booking bloods; FBC, Group VDRL, HIV, Hepatitis,
Rubella, Blood Glucose, ElectrophoresisMidwife
16 Obstetrician Discuss scan findings — confirm
expected date of birth
General including blood pressure, Wt/gain,
abdominal exam, foetal heart auscultation
Screening bloods
Midwife Urinalysis
20 Obstetrician Detailed scan of the foetus, oral
glucose tolerance test, iron studies
Medical, obstetric and social history; blood pressure;
Wt/gain, explain MSSU, provide written information
Urinalysis
Sonographer
24 Information and discussion, assess
education needs
General, assess BMI and Wt/gain Blood Pressure(BP), Urinalysis
Fundal Height (FH), Foetal Movement (FM)
26 Obstetrician Planning meeting with anaesthetist
and obstetrician
General, assess BMI and Wt/gain Consider need for antenatal steroids
28 Obstetrician Rhesus disease information and discussion General, assess BMI and Wt/gain Bloods Antibodies, blood glucose,
BP, Urinalysis FH and FM
Ultrasound/foetal growth scan
32 Obstetrician Information and discussion Provide cot death leaflet, general and
assess BMI and Wt/gain
BP; Urinalysis; FM and FH
Midwife Introduce prevention of cot death
34 Obstetrician Information and discussion General BP; Urinalysis FM and FH
Midwife Successful breast feeding Ultrasound/foetal growth scan
36 Obstetrician Information and discussion General, assess presentation, assess
BMI and Wt/gain
General; BP; Urinalysis FH and FM
Midwife Prepare for postnatal period
38 then weekly Obstetrician Reiterate signs that labour is
commencing discuss latent phase
General Assess BMI and Wt/gain BP; Urinalysis; FH and FM
Midwife
41 Obstetrician Consider induction
Midwife
BMI— body mass index BMI, MSSU—mid stream specimen of urine, Weight/weight gain (Wt/gain) (approx 0–2.5 kg in the 1st trimester and 0.5 kg per week thereafter) Carers refer to the Obstetric team but wherever
possible appointments and investigations should coincide with those of the CF team for patient convenience.
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